Titlpage
Dasotraline (SEP -225289) 
Clin
ical Study  Protocol SEP360-311 
Dasotral
ine (2mg) in Children Aged 6 to 12 Years with Attention -
Deficit Hyperactivity Disorder (ADHD): A Randomized, 
Multicenter, Double-blind, Placebo -controlled, Parallel -group 
Study of Efficacy and Safety in a Laboratory Classroom Setting
IND No. [ADDRESS_29105] 
Marlborough, MA [ZIP_CODE], [LOCATION_003] 
(508) 481 -6700  

Protocol SEP360-311, Version 3.00 Dasotraline  
Confidential and Proprietary 2 19 November 2017 RESTRICTED DISTRIBUT ION OF PROTOCOLS  
This document contains information confidential and/or of proprietary interest to Sumitomo 
Dainippon Pharma Co. Ltd. and/or Sunovion Pharmaceuticals Inc. (including their 
The information cannot be disclosed to any third party or predecessors,  subsidiaries or affiliates). 
used for any purpose other than the purpose for which it is being submitted without the prior 
written consent of the appropriate Sumitomo Dainippon Pharma Company. 
This information is being provided to you for the purpose of conducting a clinical study for 
Sunovion Pharmaceuticals Inc. You may disclose the contents of this protocol to the study 
personnel under your supervision and to your Institutional Review Board or Independent Ethics 
Committee for the above purpose. You may not disclose the contents of this protocol to any 
other parties, unless such disclosure is required by [CONTACT_24619], without the 
prior written permission of Sunovion Pharmaceuticals Inc. 
Any data gathered during the conduct of this prot ocol and supplemental information (e .g., a  
protocol amendment) that may be added to this document is also proprietary to Sunovion 
Pharmaceuticals Inc, and should be handled consistently with that stated above. This document 
contains information confidential and/or of proprietary interest to Sumitomo Dainippon Pharma 
Co. Ltd. and/or Sunovion Pharmaceuticals Inc. (including their predecessors, subsidiaries or 
The information cannot be disclosed to any third party or used for any purpose other affiliates). 
than the purpose for which it is being submitted without the prior written consent of the 
appropriate Sumitomo Dainippon Pharma Company. 
Protocol SEP360-311, Version 3.00 Dasotraline  
Confidential and Proprietary 3 19 November 2017 EMERGENCY CONTACTS  
Table 1: Emergency Contact [CONTACT_29932]/Pregnancy Reporting    
Protocol SEP360-311, Version 3.00 Dasotraline  
Confidential and Proprietary 4 19 November 2017 1. SYNOPSIS
Name [CONTACT_790]: Sunovion Pharm aceuticals Inc.  
Name [CONTACT_791]:  Dasotraline (SEP -225289) 
Title of Study: Dasotraline (2mg) in Children Aged 6 to 12 Years with Attention- Deficit Hyperactivity 
Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group 
Study of Efficacy and Safety in a Laboratory Classroom Setting  
Proposed Indication: Attention -Deficit Hyperactivity Disorder (ADHD)  
Study Centers:  Approximately 5 centers in North America  
Planned Study Period:  4-6 months  
Study Objectives : 
Primary: To evaluate the efficacy of dasotraline 2 mg/day compared to placebo on attention- deficit 
hyperactivity disorder (ADHD) symptoms in children (6 ‚Äì 12 years of age) , who weigh ‚â§ 30 kg,  in a 
laboratory classroom setting.  
Secondary: 
‚Ä¢To evaluate the efficacy of dasotraline 2 mg/day compared to placebo on ADHD symptoms
throughout the day ([ADDRESS_29106]- dose) in children in a laboratory classroom setting.
‚Ä¢To evaluate the safety and tolerability of dasotraline 2 mg/day using physical examinations,
12-lead electrocardiograms (ECG), vital signs, adverse event (AE) reports, clinical laboratory
results, and the Columbia ‚Äì Suicide Severity Rating Scale ( C-SSRS) Children‚Äôs Assessment.
Study Design: This is a randomized, double-blind, placebo-controlled, parallel-group, efficacy and 
safety study in children with ADHD in a laboratory classroom setting. The study will be comprised of 
3 periods: Screening (up to 35 days) including a 3 - 5 day ADHD medication washout prior to Day  -1, 
if necessary ; Double- blind randomized treatment  with either dasotraline ( 2 mg /day) or placebo for 
14 days; and a final safety evaluation [ADDRESS_29107] dose.  Prior to the start of treatment ( Day 1) and 
follo wing the conclusion of the double-blind period ( Day 15), subjects will undergo a full- day 
laboratory classroom evaluation in  cohorts of up to 18 subjects . Each laboratory classroom day will 
include seven 30- minute simulated classroom sessions where trained  observers will assess subjects 
using the Swanson, Kotkin, A gler, M-Flynn, and Pelham (SKAMP) Scale. In addition during each 
classroom session, a [ADDRESS_29108] (Permanent Product Measure of Performance [PERMP]) will 
be administered to evaluate sustai ned attention and effort. Seven (¬±  2) days after the last dose of study 
drug, subjects will return to the clinic and complete safety assessments.  
The primary efficacy endpoint will be the change from baseline to Day  15 in ADHD symptoms as 
measured by [CONTACT_941] m ean SKAMP -Combined score obtained from an average of the 7 SKAMP 
assessments collected across the 12 -hour classroom day . The SKAMP is a validated 13 -item rating 
scale that assesses manifestations of ADHD in a classroom setting through a combined score and 2 subscale scores; deportment items (interacting with other children, interacting with adults, remaining 
quiet, staying seated, complying with the teacher‚Äôs directions, and following the classroom rules) and attention items (getting started, sticking with tasks, attending to an activity, making activity transitions, 
completing assigned tasks, performing work accurately, and being neat and careful while writing or 
drawing). The PERMP is a [ADDRESS_29109] consisting of 80 problems per page (total of 
400 prob lems); both attempted problems and correct problems will be assessed. Subjects are to 
complete as many problems as possible in [ADDRESS_29110] administered at screening. 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Proprietary 5  19 November 2017 Safety  and tolerability  will be  monitored  throu ghout the study by [CONTACT_29933],  12-lead ECG,  vital signs,  AEs, clinical laboratory evaluations (hematology,  chem istry, 
and urinalysi s), and the C-SSRS. A Data and Safety Monitoring Board (DSMB) will review safety and 
tolerability data including data on AEs and serious AEs at regular intervals.  
Screening: The screening period will be completed within a maximum of [ADDRESS_29111]‚Äôs parents/legal guardians.  
Subjects will be confirmed as meeting DSM-5 criteria for a diagnosis of ADHD. Subjects may be 
either currently untreated or recei ving stimulan t ADHD medication at Screening.  On Day  -7 the 
ADHD Rating Scale Version  IV - Home Version (modified for investigator administration) 
(ADHD -RS-IV HV)  will be completed and subjects will attend a half -day practice laboratory classroom 
session intended to familiarize them with classroom schedules and procedures related to SKAMP evaluations, PERMP tests, and other planned activities. Any subjects receiving stimulant medication for 
ADHD will discontinue that ADHD treatment for [ADDRESS_29112]‚Äôs parent/legal guardian will be contact[CONTACT_29934] . Clinical ly significant is defined as an ADHD -RS-IV HV total score ‚â•  26 following a 
minimum 72-hour washout from any prior ADHD treatment.  Subjects who do not demonstrate 
clinically significant symptoms  (i.e., ADHD- RS-IV ‚â• 26) on Day -1 will be considered screen failures 
and will not be  eligible for  randomiz ation.  
Subjects may be rescreened a maximum of 2 times for out of range clinical laboratory results, 
insufficient medicati on washout periods, etc. 
Double -blind Period: On Day 1 subjects will return to the clinic in the morning, and those m eeting all 
inclusion and no exclusion  criteria  will be randomized  (1:1) to receive 2 mg/day dasotraline, or placebo, 
and will attend classroom sessions in which they will be evaluated for ADHD symptoms using the 
SKAMP assessment. During this baseline classroom assessment ( Day 1), subjects will be evaluated at 
regular intervals: approximately 8  AM, 10 AM , 12 PM , 2 PM , 4 PM , 6 PM,  and 8  PM. Sub jects will 
begin taking study drug on th e evening  of Day 1 (with or without food) after the final, 8:[ADDRESS_29113] leaves, or at home. On the night ( Day 14) before the  
second classroom day, study drug must be taken at approximately [ADDRESS_29114]‚Äôs parent/legal guardian daily with a 
reminder to administer study drug . A dosing diary will be provided to the parent/legal guardian  to record the 
date and time of each administration of study drug. On Day  15 subjects will return to the clinic in the 
morning at 6:30 AM and classroom sessions will be started at approximately 8  AM, 10 AM, 12 PM , 
2 PM , 4 PM , 6 PM,  and 8 PM  to coincide with 12, 14, 16, 18, 20, 22, and 24 hour s following the 
Day 14 dose.  
End of Study: Seven (¬±2)  days after the last dose of study drug, all subjects will return to the clinic 
and complete assessments. A fter the EOS visit, all subjects will be referred for continuation of their 
care as determined by [CONTACT_093]. Additionally, for subjects who complete the study or discontinue for tolerability or lack of efficacy reasons, the sponsor will provide support for approved 
ADHD medication costs for up to [ADDRESS_29115]‚Äôs healthcare provider. 
A study schematic is presented in Figure  1. A summary  of assessments to be conducted at each 
visit is  presented in Table 2, Schedule of Assessments. 
3URWRFRO6(39HUVLRQ  'DVRWUDOLQH
&RQILGHQWLDODQG3URSULH WDU\  1RYHPEHU$VDPSOH&ODVVURRP' D\LVSUHVHQWHGLQ 7DEOH
6WXG\6FKHPDWLF


1XPEHURI6XEMHFWVSODQQHG 7KLVVWXG\LVSURMHFWHGWRUDQGRPL]HDSSUR[LPDWHO\VXEMHFWV 
SHUWUHDWPHQWJURXS 
'LDJQRVLVDQG0DLQ&ULWHULDIRU6XEMHFW,QFOXVLRQ
0DOHRUIHPDOHVXEMHFWVEHWZHHQDQG\HDUVRIDJH
6XEMHFWZHLJKV¬îNJDWWKHWLPHRIVFUHHQLQJ
6XEMHFWVLQJHQHUDOJRRGKHDOWKDUHHOLJLEOHWRSDUWLFLSDWH
6XEMHFWVPXVWPHHW'LDJQRVWLFDQG6WDWLVWLFDO0DQXDORI0HQWDO 'LVRUGHUV)LIWK(GLWLRQ
'60FULWHULDIRUDSULPDU\GLDJQRVLVRI$'+'LQDWWHQWLYH K\SHUDFWLYHRUFRPELQHG
SUHVHQWDWLRQDWVFUHHQLQJHVWDEOLVKHGE\DFRPSUHKHQVLYHSV\F KLDWULFHYDOXDWLRQWKDWUHYLHZV
'60FULWHULD'LDJQRVLVZLOOEHFRQILUPHGDWVFUHHQLQJXVLQJ WKH6FKHGXOHIRU$IIHFWLYH
'LVRUGHUVDQG6FKL]RSKUHQLDIRU6FKRRO$JH&KLOGUHQ3UHVHQWDQ G/LIHWLPH9HUVLRQ
.6$'63/
6XEMHFWLVFXUUHQWO\HLWKHUXQWUHDWHGIRU$'+'RUUHFHLYLQJDW UHDWPHQWUHJLPHQRIDVWLPXODQW
PHGLFDWLRQSUHVFULEHGDVPRQRWKHUD S\WUHDWPHQWZLWKLQWKHDSSUR YHGODEHOHGGRVHUDQJHIRU
$'+'
6XEMHFWLQWKHRSLQLRQRIWKHLQYHVWLJDWRULVQRWWUHDWPHQWU HIUDFWRU\
)RUDQ\VXEMHFWUHFHLYLQJPRQRWKHUDS\VWLPXODQWWUHDWPHQWIRU$ '+'WKDWWUHDWPHQWPXVWEH
ZHOOWROHUDWHGDQGFOLQLFDOO\HIIHFWLYH1RWH,IDQ\GRVHVRI $'+'SKDUPDFRWKHUDS\ZHUH
PLVVHGGXULQJWKHZHHNSULRUWR'D\WKHVXEMHFW¬∂VHOLJLELOL W\ZLOOEHGLVFXVVHGZLWKWKH
0HGLFDO0RQLWRU
6XEMHFWRQ'D\KDVHYLGHQFHRIFOLQLFDOO\VLJQLILFDQW$'+' V\PSWRPVDVPHDVXUHGE\DQ
$'+'56,9+9WRWDOVFRUH¬ï,IVXEMHFWKDVEHHQUHFHLYLQJV WLPXODQWSKDUPDFRWKHUDS\
IRU$'+'WKH$'+'56,9VKRXOGEHDGPLQLVWHUHGIROORZLQJDPLQL PXPKRXUZDVKRXW
IURPSULRU$'+'PHGLFDWLRQWUHDWPHQW


Protocol SEP360-311, Version 3.[ADDRESS_29116] Exclusion:  
Subjects with any of the following conditions are ineligible for participation in the study:  
1. Subject currently has a diagnosis of ast hma that has required daily treatment with 
bronchodilators or nebulizer treatments in the 30 days prior to screening and/or who may 
require daily treatments with these agents over the course of the trial (intermittent use of 
bronchodilators is not exclusionary; subjects who have a history of requiring persistent asthma 
treatment should be discussed with the medical monitor prior to randomization). 
2. Subject has a diagnosis of bipolar  I or II disorder, major depressive disorder, conduct disorder, 
obsessive- compulsive disorder, disruptive mood dysregulation disorder ( DMDD), intellectual 
disability, any history of psychosis, autism spectrum disorder, Tourette‚Äôs Syndrome, or 
confirmed genetic disorder with cognitive and/or behavioral disturbances; generalized anxi ety 
disorder or panic disorder that has been the primary focus of treatment at any time during the 
12 months prior to screening ; or that required pharmacotherapy any time during the [ADDRESS_29117] has failed 2 adequate courses (dose and duration) of stimulant or non- stimulant 
treatment for ADHD. 
4. Subject is considered treatment refractory by [CONTACT_093].  
5. Subject shows evidence of any chronic disease of the central nervous system (CNS) such as 
tumors, inflammation, seiz ure disorder, vascular disorder, potential CNS related disorders that 
might occur in childhood. 
6. Subjects with a history of persistent neurological symptoms attributable to serious head injury; 
history of febrile seizure, drug-induced seizure, or alcohol wi thdrawal seizure .  
7. Any use of anticonvulsants for seizure control currently or within the past 2  years . 
8. Uncontrolled thyroid disorder indicated by [CONTACT_21923] (TSH) ‚â§ 0.8 x the 
lower limit of normal ( LLN ) or ‚â• 1.25 x the upper limit of normal ( ULN) for the reference 
laboratory. 
9. Any history of attempted suicide , clinically significant suicidal ideation, or answers ‚Äúyes‚Äù to 
‚ÄúSuicidal Ideation‚Äù item  4 or item 5 for any lifetime history on the C- SSRS Children‚Äôs 
Lifetime/Recent assessment at screening.  
10. Subjects having first -degree relatives (biological parent or sibling) with a history of 
schizophrenia, schizoaffective disorder, bipolar I disorder, or bipolar II disorder ar e also 
ineligible for the study.  
Investigational Product, Dosage and Mode of Administration: Each daily dose will be supplied as 
one 2 mg dasotraline capsule for oral administration.  
Duration of Treatment: 2 weeks 
Reference Therapy, Dosage and Mode of A dministration: Each daily dose will be supplied as one 
matching placebo capsule for oral administration.  
Selected Concomitant Medications: Subject must not have taken any of the following medications: 
anticonvulsants for seizure control within 2 years pri or to screening; antipsychotic medication within 
6 months prior to screening; herbal and/or complementary treatments, e.g., St. John‚Äôs Wort, or 
antidepressant medications (e.g., bupropi[INVESTIGATOR_2394], serotonin norepi[INVESTIGATOR_26331] [SSRI]/ 
selective serot onin reuptake inhibitor [SNRI] , tricyclic, etc. ) within 6  months prior to Day 1, 
monoamine oxidase (MAO) inhibitors at any time, or non-stimulant product as treatment for ADHD within [ADDRESS_29118] dose of study drug. 
Use of any of the following medications is not permitted during the study from screening through the EOS visit: lithium; alpha -2 adrenergic receptor agonists (including clonidine and guanfacine), 
modafinil, armodafinil, atomoxetine, or any stimulant class agent (methylphenidate- or amphetamine-
based); antidepressant med ications (e.g., bupropi[INVESTIGATOR_2394], SSRI/SNRI, MAO inhibitor, tricyclic, etc.); 
anticonvulsant medications (e.g., phenytoin, carbamazepi[INVESTIGATOR_050], lamotrigine, valproic acid, etc.); 
antipsychotic medications; pseudoephedrine -containing medications; medications with significant 
effect on blood pressure or heart rate (intermittent use of asthma treatments is permitted but should be discussed with the medical monitor); sleep aids (with the exception of melatonin); diphenhydramine 
except topi[INVESTIGATOR_29899]; herbal and/or com plementary treatments, e.g., St. John‚Äôs Wort; or 
CYP2B6 substrates or inhibitors or inducers of CYP2B6. Subjects who require persistent asthma 
treatment during the study should be discussed with the medical monitor as they may be required to be 
discontinued from the study. 
Use of any of the following behavioral interventions is not permitted during the study from s creening 
through the EOS visit. This includes: ongoing or newly initiated Cognitive Behavioral Therapy (CBT) 
for the treatment of ADHD; behaviora l therapi[INVESTIGATOR_014], including school based interventions that were 
initiated less than one month prior to screening; and, behavioral therapy that in the opi[INVESTIGATOR_29900]‚Äôs ability to participate for the duration of the study. 
School based interventions that have been in place for more than one month prior to screening will be allowed. 
Note: Unavoidable changes in school- based interventions that occur during study participation will not 
be exclusionary, but should be documented by [CONTACT_093], to the extent possible. Subjects should 
not be enrolled who, in the judgment of the investigator, are expected to start substantially different or 
more intensive course of behavioral therapy over the duration of their participation in the study.  
Study Endpoints:  
Primary Endpoint: Change from baseline at Day  15 in ADHD symptoms as measured by [CONTACT_29935] -Combined score obtained from an average of the 7 assessments collected across the 12 -hour 
classroom day ([ADDRESS_29119]-dose). 
Secondary Endpoints:  
‚Ä¢ Mean SKAMP -Combined score from the 7 assessments collected across the 12 -hour classroom day 
([ADDRESS_29120]-dose ) on Day  15. 
‚Ä¢ SKAMP -Combined score at each of the assessment times ([ADDRESS_29121]-dose ) dur ing the classroom day on Day  15. 
‚Ä¢ Change from baseline at Day 15 in SKAMP-Combined score at each of the assessment times ([ADDRESS_29122]-dose ) dur ing the classroom day. 
‚Ä¢ Change from baseline at Day 15 in mean SKAMP-Attention subscale score obtained from the 
7 assessments collected across the 12 -hour classroom day ([ADDRESS_29123]-dose). 
‚Ä¢ SKAMP -Attention subscale score at each of the assessment times ([ADDRESS_29124]-dose ) during t he classroom day on Day  15. 
‚Ä¢ Change from baseline at Day 15 in SKAMP- Attention subscale score at each of the assessment 
times ([ADDRESS_29125]-dose ) dur ing the classroom day. 
‚Ä¢ Change from baseline at Day 15 in mean SKAMP -Depor tment subscale score obtained from the 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Proprietary 9  19 November 2017 7 assessments collected across the 12 -hour classroom day ([ADDRESS_29126]-dose). 
‚Ä¢ SKAMP -Deportment subscale score at each of the assessment times ([ADDRESS_29127] -dose) during the classroom day on Day  15. 
‚Ä¢ Change from baseline at Day 15 in SKAMP- Deportment subscale score at each of the assessment 
times ([ADDRESS_29128]-dose ) dur ing the classroom day. 
‚Ä¢ Change from baseline at Day [ADDRESS_29129] Problems scores at each of the 
assessment times ([ADDRESS_29130] -dose ) during the classroom day . 
‚Ä¢ PERMP- Attempted and Correct Problems scores at each of the assessment times ([ADDRESS_29131]-dose) during the classroom day on Day  15. 
‚Ä¢ Change from baseline at Day 15 in mean PERMP -Attempted score obtained from an average of the 
7 assessments collected across the 12 hour classroom day ([ADDRESS_29132]-dose). 
‚Ä¢ Change from baseline at Day [ADDRESS_29133] score obtained from an average of the 
7 assessments collected across the 12 hour classroom day ([ADDRESS_29134]-dose). 
‚Ä¢ The incidence of overall AEs, serious AEs (SAEs), and AEs (or SAEs) leading to discontinuations. 
‚Ä¢ Absolute values and change from baseline in clinical laboratory evaluations (serum chemistry, 
hematology, and urinalysis). 
‚Ä¢ Absolute values and changes from baseline in vital signs, body weights, and 12- lead ECGs . 
‚Ä¢ Frequency and severity of suicidal ideation and suicidal behavior as assessed by [CONTACT_941] C-SSRS.  
Statistical Methods:  
Hypotheses:  
Let Œº 2mg/day, and Œº PBO represent the changes from baseline at Day 15 in mean SKAMP-Combined score 
for dasotraline 2 mg /day,  and placebo arms, respectively. The following hypothesi s wil l be tested to 
compare the mean change value between the dasotraline 2 mg /day group and the placebo group from 
baseline to Day  15: 
1. Dasotraline 2 mg /day versus placebo:  
 H 01: Œº2mg/day = Œº PBO versus H 11: Œº2mg/day ‚â† Œº PBO  
Efficacy Analysis: 
An analysis of covariance (ANCOVA) will be applied to evaluate the treatment effect for the primary 
efficacy endpoint between the dasotraline 2  mg/day and placebo groups for the intent -to-treat (ITT) 
population. The model will include treatment, mean SKAMP -Combined score at baseline, and site as 
fixed effects. T he primary efficacy analysis will be repeated for the per protocol (PP) population. To 
explore the robustness of the primary efficacy analysis of change from baseline at Day 15 in ADHD 
symptoms in mean SKAMP-Combine d score, 2  sensitivity analyses will be performed, a placebo -based 
multiple imputation pattern -mixture model (PMM) and a tippi[INVESTIGATOR_29901]. 
A similar ANCOVA model, as described above, will be used for the secondary efficacy endpoints for  
the ITT population. 
Multiplicity Considerations: There will be no adjustment for multiplicity for the primary efficacy 
analysis, secondary efficacy analyses, or safety analyses.  
Safety Analysis:  
All safety analyses will be performed on the safety population. Overall  AEs (or SAEs)  and AEs (or 
SAEs)  leading to discontinuat ion w ill be  summar ized by [CONTACT_29936]. Descriptive  statistics  also will be 
provided by [CONTACT_29937]:  
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Proprietary 10  19 November 2017 laboratory tests, vital signs,  and ECG  parameters. Frequency  and severity  of suicidality , as captured by 
[CONTACT_941] C-SS RS, will be summarized  by [CONTACT_765].  
Sample Size:   
A post- hoc ANCOVA-L OCF analysis of data from the SEP360-[ADDRESS_29135] of dasotraline 4  mg/day versus placebo in a subset of pediatric patients  
with ADHD aged [ADDRESS_29136] size in this subgr oup of 0.95 (LS mean 
difference at Week  [ADDRESS_29137] error of 2.2). A ssum ing a smaller effect size for 
dasotraline 2  mg/day vs. placebo than that of dasotraline 4 mg/day vs. placebo, an effect size of 0.[ADDRESS_29138] size of 0.7 for  dasotraline 2  mg/day compar ed to placebo on the primary 
efficacy endpoint of mean SKAMP -Combined score obtained from the average of 7  assessments 
collected across the 12 -hour classroom day, 88 subjects (44 per treatment group) will provide 90% 
power to detect a treatment effect between dasotraline and placebo at the two -sided alpha level of 0.05, 
based on the two- sample t -test with equal variance procedure. 
The study will target approximately [ADDRESS_29139] s (50 per treatment group) randomized to either placebo 
or dasotraline 2 mg/day in an attempt to have 88 subjects complete the trial (assuming a 12% overall 
dropout rate).  
 
Protocol SEP360-311, Version 3.00   
Confidential and Proprietary 11  19 November 2017 Table 2: Schedule of Assessments  
Procedures  Screening  
Double-blind Period  End of 
Study  
Clinic Visit  Practice 
Laboratory 
Classroom 
Session  Telephone 
Contact  [CONTACT_29938] - 
Visit 1  Visit 2  Visit 3 Visit 4 Visit 5 Visit 6 
Day -35 
to -8 Day -7 
Day -1 Day 1 Day 15 Day 21a 
(¬± 2) 
Obtain  infor med consent  X      
Obtain informed assent  X      
Inclusion/E xclusion 
criteria X X X X   
Randomization     X   
Disp ense study  drug    X   
Study drug  
accountability      X  
Medical  Histo ry X      
Psychiatric  Histo ry X      
Family Psychiatric 
History  X      
Prior/conco mitant 
medication review  X X X X X X 
K-SADS -PL X      
Physical examination  X     X 
Neurological  
examination  X     X 
Height X      
Weight  
(including body mass  
index) X  
 X X X 
Vital signs  X X  Xb Xb X 
Electrocardiogram  
(ECG) X     X 
Adverse event  
monitoringf     X X 
Colu mbia Suicide 
Seve rity Rating Scale 
(C-SSRS) X X  X X X 
Protocol SEP360-311, Version 3.00   
Confidential and Proprietary 12  19 November 2017 Table 2: Schedule of Assessments  (Continued)  
Procedures  Screening  
Double -blind Period  End of 
Study  
Clinic Visit  Practice 
Laboratory 
Classroom 
Session  Telephone 
Contact  [CONTACT_29938] - 
Visit 1  Visit 2  Visit 3 Visit 4 Visit 5 Visit 6 
Day -35 
to -8 Day -7 
Day -1 Day 1 Day 15 Day 21a 
(¬± 2) 
ADHD -RS-IV HV  X Xg X   X 
Classroom Practice 
Sessionc  X     
SKAMPd    X X  
Math pretest for 
determination of math 
level  X  
    
PERMPd    X X  
Dosing diary 
distribution/review     X X  
Hematology/Chemistry X     X 
TSH  X      
Serum Œ≤-hCG  (in 
females ‚â•  8 years of 
age)e X  
   X 
Urinal ysis X     X 
Urine  drug screen  X   X X X 
Urine  Œ≤-hCG  (in females 
‚â• 8 years of age)e    X X  
Abbreviations:  ADHD -RS-IV HV = ADHD Rating Scale Version IV Home Version (modified for investigator 
administration), Œ≤-hCG  = beta-human chorionic gonadotropin, K -SADS -PL = Schedule for Affective Disorders and 
Schizophrenia for School -Age Children - Present and Lifetime version , PERMP  = Permanent Product Measure of 
Performance, SKAMP  = Swanson, Kotkin, A gler, M-Flynn, and Pelham Scale, TSH = thyroid stimulating hormone  
a Seven ( ¬± 2) days after the last dose of study drug, all subjects will return to the clinic and complete assessments.  
b Heart rate and blood pressure will be measured at approximately the same time on Day [ADDRESS_29140] on Day  -9, -8, or -7. 
 
Protocol SEP360-311, Version 3.00   
Confidential and Proprietary 13  19 November 2017 Table 3: Sample Laboratory Classroom Day Schedule (Day 15) 
Nominal Time  Actual Time  Arrival  PERMP/SKAMP  Meal/snack  Dismissal  
 6:30 am  X    
 7:[ADDRESS_29141] -dose 8:00 am   X   
 9:[ADDRESS_29142] -dose 10:[ADDRESS_29143] -dose 12:00 pm   X   
 12:[ADDRESS_29144] -dose 2:00 pm   X   
 2:[ADDRESS_29145] -dose 4:[ADDRESS_29146] -dose 6:00 pm   X   
 6:[ADDRESS_29147] -dose 8:00 pm   X   
 8:45 pm     X 
Abbreviation:  h = hour, PERMP = P ermanent Product Measure of Performance, SKAMP  = Swanson, Kotkin, 
Agler, M -Flynn, and Pelham Scale  
 
 
Protocol SEP360-311, Version 3.[ADDRESS_29148] Exclusion Criteria  ..........................................................................................36  
9. STUDY DRUG MATERIALS  AND MANAGEMENT  ...........................................40  
9.1. Description of Study Drug ..........................................................................................40  
9.2. Study Drug Packaging and Labeling  ..........................................................................40  
9.2.1.  Package Description  ...................................................................................................40  
9.2.2.  Labeling Description  ..................................................................................................40  
9.3. Study Drug Storage  .....................................................................................................41  
9.4. Dispensing of Study Drug ..........................................................................................41  
9.5. Study Drug Accountability .........................................................................................41  
9.6. Study Drug Handling and Disposal ............................................................................42  
10. TREATMENT OF SUBJECTS ..................................................................................43  
10.1.  Study Medication  ........................................................................................................43  
10.2.  Treatment Compliance  ................................................................................................43  
10.3.  Concomitant Medications and Therapi[INVESTIGATOR_014] ...................................................................43  
10.3.1.  Prohibited Medications ...............................................................................................44  
10.4.  Restrictions  .................................................................................................................45  
10.5.  Contraception Requirements ......................................................................................45  
10.6.  Guidance for Overdose ...............................................................................................45  
10.7.  Cautions ......................................................................................................................46  
10.8.  Dietary Guidelines  ......................................................................................................46  
11. STUDY ASSESSMENTS  ..........................................................................................47  
11.1.  Demographics an d Baseline Characteristics  ...............................................................47  
11.2.  Eligibility Assessments  ...............................................................................................47  
11.3.  Efficacy Assessments  .................................................................................................48  
11.4.  Safety Assessments  .....................................................................................................48  
11.4.1.  Adverse Events  ...........................................................................................................48  
11.4.2.  Clinical Laboratory Tests  ...........................................................................................48  
11.4.3.  Vital Signs  ..................................................................................................................49  
11.4.4.  Physical and Neurological Examinations  ...................................................................49  
11.4.5.  Weight and Body Mass Index .....................................................................................49  
11.4.6.  ECGs  ...........................................................................................................................49  
11.4.7.  Safety Scales  ...............................................................................................................49  
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  16 19 November 2017 11.5.  Study Visits and Assessments  ....................................................................................50  
11.5.1.  Screening  ....................................................................................................................50  
[IP_ADDRESS].  Visit 1 (Day -35 to  -8) ................................................................................................50  
[IP_ADDRESS].  Visit 2 (Day  -7): Practice Laboratory Classroom Session  ..........................................50  
[IP_ADDRESS].  Visit 3 (Day  -1): Telephone Contact  ..........................................................................51  
11.5.2.  Double-blind Period ....................................................................................................51  
[IP_ADDRESS].  Visit 4 (Day  1): First Laboratory Classroom Day  ......................................................51  
[IP_ADDRESS].  Visit 5 (Day  15): Second Laboratory Classroom Day ................................................52  
11.5.3.  Visit 6 (Day  21 ¬± 2): End of Study .............................................................................[ADDRESS_29149] FROM STUDY/DISCONTINUATION OF 
STUDY DRUG  ...........................................................................................................[ADDRESS_29150] Disposition  .....................................................................................................61  
15.3.2.  Drug Exposure and Compliance .................................................................................61  
15.3.3.  Important Protocol Deviations ....................................................................................61  
15.3.4.  Demographic and Baseline Characteristics  ................................................................61  
[IP_ADDRESS].  Medical History  ..........................................................................................................61  
[IP_ADDRESS].  Psychiatric History  ......................................................................................................62  
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  17 19 November 2017 [IP_ADDRESS].  Family Psychiatric History  .........................................................................................62  
15.3.5.  Efficacy Analyses  .......................................................................................................62  
[IP_ADDRESS].  Primary Efficacy Endpoint Analysis ..........................................................................62  
[IP_ADDRESS].  Secondary Efficacy Endpoint Analysis ......................................................................62  
[IP_ADDRESS].  Adjustment for Multiplicity  ........................................................................................63  
[IP_ADDRESS].  Subgroup Analysis ......................................................................................................63  
15.3.6.  Safety Analyses  ..........................................................................................................63  
[IP_ADDRESS].  Adverse Events  ...........................................................................................................64  
[IP_ADDRESS].  Clinical Laboratory Assessments  ...............................................................................65  
[IP_ADDRESS].  ECGs  ...........................................................................................................................65  
[IP_ADDRESS].  Vital Signs  ..................................................................................................................65  
[IP_ADDRESS].  Neurological Examination  ..........................................................................................65  
[IP_ADDRESS].  Concomitant Medications ...........................................................................................65  
[IP_ADDRESS].  Columbia- Suicide Severity Rating Scale (C -SSRS)  ...................................................65  
[IP_ADDRESS].  Subgroup Analysis ......................................................................................................65  
15.3.7.  Treatment of Missing Data  .........................................................................................65  
15.3.8.  Sensitivity Analyses  ....................................................................................................66  
16. PROCEDURE FOR CLINICAL STUDY QUALITY CONTROL /DATA 
COLLECTION, MANAGEMENT, AND QUALITY ASSURANCE  ......................67  
16.1.  Data Collection/Electronic Data Capture (EDC)  ........................................................[ADDRESS_29151] Privacy  ...........................................................................................................71  
17.5.  Protocol Amendments and Emergency Deviations ....................................................72  
17.6.  Records Retention  .......................................................................................................72  
17.7.  Inspection of Records .................................................................................................72  
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  18 19 November 2017 17.8.  Financial Disclosure  ...................................................................................................72  
17.9.  Publication Policy  .......................................................................................................72  
18. REFERENCES  ...........................................................................................................74  
19. INVESTIGATOR APPROVA L .................................................................................76  
20. APPENDIX I. CARDIAC  SAFETY  MONITORING (ECG)  ....................................77  
21. APPENDIX II. BODY MASS INDEX DETERMINATION  ....................................78  
22. APPENDIX III.  CLINICAL  LABORATORY T ESTS  ..............................................79  
23. APPENDIX IV.  CLINICALLY RELEVANT CYP2B6 SUBSTRATES OR  
INDUCERS OR INHIBITORS (GENERIC NAMES)  ..............................................80  
24. APPENDIX V.  GROWTH CHART (MA LE). ...........................................................81  
25. APPENDIX VI.  GROWTH CHART (FEMALE )......................................................[ADDRESS_29152] OF TABLES  
Table 1:  Emergency Contact [CONTACT_7171] ...................................................................................3  
Table 2:  Schedule of Assessments  ............................................................................................11  
Table 3:  Sample Laboratory Classroom Day Schedule (Day 15) .............................................13  
Table 4:  List of Abbreviations ..................................................................................................19  
Table 5:  Definition of Key Study Terms  ..................................................................................22  
Table 6:  Investigational Product ...............................................................................................40  
Table 7:  Computerized Systems Used for Source Data ............................................................[ADDRESS_29153] OF FIGURES  
Figure  1: Study Schematic  .........................................................................................................[ADDRESS_29154] OF ABBREVIATION S AND DEFINITIONS OF TERMS 
The abbreviations and the definition of key study terms used in the clinical study protocol are 
shown in Table 4 and Table  5. 
Table 4: List of Abbreviations 
Abbreviation  Full Form  
ADHD  Attention deficit hyperactivity disorder  
ADHD -RS-IV  ADHD Rating Scale Version IV   
ADHD -RS-IV HV  ADHD Rating Scale Ve rsion  IV - Home Version (modified for 
investigator administration)  
AE Adverse event  
ANCOVA Analysis of covariance  
ATC  Anatomical therapeutic chemical (class)  
BMI  Body mass index  
CAP  College of American Pathologists  
CBT  Cognitive Behavioral Therapy 
CFR Code of Federal Regulations 
CGI-S Clinical Global Impression ‚ÄìSeverity of Illness  
CLIA  Clinical Laboratory Improvement Amendments 
CNS  Central nervous system  
CRF  Case report form  
CRO  Contract research organization  
C-SSRS  Columbia Suicide Severity R ating Scale  
CTM  Clinical trial material  
DAT  Dopamine transporter 
DBL  Database lock  
DEA Drug Enforcement Agency 
DHPG  3, 4-dihydroxyphenylglycol 
DMDD Disruptive mood dysregulation disorder 
DMP  Data Management Plan  
DNRI  Dopamine and norepi[INVESTIGATOR_238], re uptake inhibitor  
DSM -IV-TR Diagnostic and Statistical Manual for Mental Disorders Fourth 
Edition; Text Revision  
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  20 19 November 2017 Table 4: List of Abbreviations (Continued)  
Abbreviation  Full Form  
DSM -[ADDRESS_29155]  Lower limit of normal 
MAO Monoamine oxidase (inhibitor)  
MDD Major depressive disorder  
MedDRA  Medical Dictionary for Re gulatory Activities  
NET  Norepi[INVESTIGATOR_29902] -mixture model 
POC  Point of care  
PP Per-Protocol 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  21 19 November 2017 Table 4: List of Abbreviations (Continued)  
Abbreviation  Full Form  
PR Time between P wave and QRS in electrocardiography  
PT Preferred term  
PVG  Pharmacovigilance  
QRS  Electrocardiographic wave (complex or interval)  
QT Electrocardiographic interval from the begin ning of the QRS 
complex to the end of the T  wave  
QTc QT interval corrected for heart rate  
QTcB  QTc with Bazett correction  
QTcF  QTc with Fridericia correction  
RR Electrocardiographic interval  between [ADDRESS_29156] Upper limit of normal 
USP [LOCATION_002] Pharmacopeia 
WHO World Health Organization 
WHO-DD World Health Organization drug dictionary 
 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  22 19 November 2017 Table 5: Definition of Key Study Terms  
Terms  Definition of terms  
CRF  A printed, optical, or electronic document designed to record all 
of the protocol required information to report to the Sponsor for 
each study subject. 
Screened Subject  Any subject who signed the study specific informed consent and completed at least one study related pr ocedure. 
Screen Failure Any subject who signed the study specific informed consent but either failed to meet study requirements during screening or met 
study requirements at screening but was not enrolled/randomized. 
Study Drug (or 
Study medication) Term  to cover investigational drug, placebo, and/or active 
control. 
Treatment P eriod  The period of the study in which the study drug is administered. 
Randomized Subject Any subject who was randomized into the treatment period of the 
study and was assigned a randomization number. 
Completed Subject Any subject who participated throughout the duration of the 
study, up to and including both visits [ADDRESS_29157] completes the study per the study design. 
 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  23 19 November 2017 4. INTRODUCTION 
4.1. Backgrou nd 
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized 
by [CONTACT_29939], hyperactivity, and impulsivity that is more severe or frequent when compared to individuals of the same developmental stage. There are a number of characteristics 
related to cognition that distinguish people with ADHD from people without ADHD including 
deficits in response inhibition ( Aron -2005, Goto -2010, Luna -2004) and reward sensitivity 
(Passarotti -2011), as well as working memory,  attention, planning, and behavioral inhibition 
(Hervey -2004, Boonstra-2005, Willcutt-2005). ADHD is prevalent in approximately 8% to  10% 
of school-aged children and approximately 2% to 5% of adults ( Ferri -2014 ). Symptoms 
experienced in childhood often persist into adolescence and adulthood, al though the 
hyperactivity component tends to diminish over time (Ferri-2014). 
The etiology of ADHD is not fully understood, but it is believed that both genetic and non-
genetic factors are implicated in the disease. Several factors related to disturbances of neonatal 
development including premature birth, low birth weight and perinatal complications have been 
shown to increase the risk of developi[INVESTIGATOR_29903] ( Perricone -2013, Botting -1997, 
Amor -2005).The neurotransmitters dopamine and norepi[INVESTIGATOR_29904] a critical 
role in the development of ADHD and thus receptors associated with these are key drug targets (Rader -2009 ).  
Current ADHD pharmacotherapi[INVESTIGATOR_29905]. In 
nonclinical microdialysis studies, ADHD drugs like amphetamine, methylphenidate, and atomoxetine increase dopamine and norepi[INVESTIGATOR_238] ‚Äì either by [CONTACT_29940] ‚Äì especially in the prefrontal cortex. At clinically -efficacious doses, 50% dopamine 
transporter (DAT) occupancies are reported with methylphenidate in adults with ADHD (Volkow-1998).  
Adrenergic signaling in the prefrontal cortex is thought to control attentional processes and thus 
contribute to working memory and executive functions ( Arnsten -2011, Gamo -2011). Consistent 
with this neuronal circuitry, norepi[INVESTIGATOR_29906] (NET) inhibition (eg, atomoxetine) alone 
is sufficient for clinical efficacy in ADHD. The stimulants amphetamine and methylphenida te 
both increase norepi[INVESTIGATOR_29907], and methylphenidate achieves 50% NET occupancy in human subjects at doses clinically efficacious in ADHD ( Hannestad -2010).  
Dasotraline (also known as SEP-225289) is a new chemical entity that is thought to produce its 
therapeutic effects in ADHD by [CONTACT_29941], as determined by 
[CONTACT_29942]. Pharmacologically, dasotraline is consistent w ith 
dopamine and norepi[INVESTIGATOR_26331] (D NRI) effects. Dasotraline is a diastereomer of 
the major metabolite of the selective serotonin reuptake inhibitor sertraline, but is not a metabolite of sertraline, nor is it converted to the desmethylated metabolite of sertraline in vivo. Unlike amphetamines, dasotraline does not increase the release of these monoamines into the 
extraneuronal space. Dasotr aline's pharmacokinetic profile  allows plasma concentrations to 
remain in a therapeutic range over the [ADDRESS_29158]  study to assess the efficacy and s afety of dasotraline in pediatric subjects  
with ADHD.  The prior 2 studies demonstrated efficacy at 4  mg in comparison to placebo. This 
study will utilize a simulated classroom setting , identical to the one used in SEP360-305, to 
evaluate the efficacy and s afety of dasotraline 2 mg/day  in pediatric subjects with ADHD. In this 
setting subjects encounter activities and interaction normally found in a typi[INVESTIGATOR_29908]. The 
laboratory school protocol ( Wigal -2006) is a particularly useful method for evaluation of 
efficacy in subjects with ADHD because it represents a controlled study setting for evaluation and comparison of study treatments. 
The present study seeks to evaluate the efficacy and safety of dasotraline 2  mg/day . Data 
supporting the safety and efficacy of both a [ADDRESS_29159] a range of 
potential doses (2-4 mg/day) for children, allowing clinicians the flexibility to achieve the 
optimal benefit/risk for each patient.  
Further information on nonclinical and other clinical studies is provided in the Investigator‚Äôs 
Brochure.  
4.3. Risk -Benefit Assessment  
There are two recently completed studies in children  with ADHD that report on the efficacy and 
tolerability of dasotraline  (SEP360-202 and SEP360-305), both of which demonstrated 
statisticall y significant improvement compared t o placebo at the 4  mg/day dose. A third study, 
SEP360-310, has been completed but the analyses are not yet finalized. 
 
SEP360-202 
SEP360- 202 evaluated the efficacy and safety of 2  doses of dasotraline (2 mg/day and 4 mg/ day) 
in pediatric subjects with ADHD.  In this 6-week double-blind, placebo controlled trial, 
dasotraline (4  mg/day) was superior to placebo, and well tolerated. 
In SEP360-202, overall, 54.1% of subjects experienced at least 1  Treatment Emergent Adverse 
Event (TEAE) during the study, 38.6% experienced a TEAE that was considered by [CONTACT_7181], and 6.7% experienced a TEAE that led to 
discontinuation of study drug. Subjects in the dasotraline 4 mg/day group experienced more 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  25 19 November 2017 TEA Es, more related TEAEs, and more TEAEs that led to a discontinuation than the dasotraline 
2 mg/day group and the placebo group, and the placebo group experienced the least in each of 
these categories. No  subjects experienced an SAE and there were no deaths  during the study. 
 
SEP360-305 
SEP360- 305 evaluated the efficacy and safety of dasotraline (4  mg/day) to placebo, in pediatrics 
with ADHD in a classroom laboratory setting over 2  weeks . The dasotraline (4  mg/day) dose 
demonstrated statistically superior efficacy when compared to placebo, and was well tolerated.  
In SEP360-305, TEAEs were more common in patients taking dasotraline compared with th ose 
taking placebo (data from the discontinued 6 mg arm of this trial are included here for safety 
consideration). TEAEs were generally mild or moderate in severity. Four patients receiving 
dasotraline experienced severe TEAEs: 4  mg/day: 1 case of insomnia and 1 case of decreased 
appetite;  6 mg/day: 2 cases of insomnia. No serious AEs occurred in patients treated with 
dasotraline. TEAEs associated with discontinuation were hallucinations (2 cases in the 6  mg/day 
group, 1 case in the 4  mg/day group), insomnia (1 case in the 4 mg/day group), decreased 
appetite (1 case in the 6  mg/day group), and rash (1 case in the 4 mg/ day group).  
 
Moreover, there have been three studies of dasotraline efficacy and tolerability in adults with 
ADHD including one long term de novo trial for safety ; SEP360-201, SEP360-301, and 
SEP360-[ADDRESS_29160] study  (SEP360-201),  a randomized, double-blind, parallel-group, outpatient study at 
30 sites , evaluated the efficacy and safety of dasotraline in adults with ADHD using 2  doses 
(4 mg/day or 8  mg/day) versus placebo over a 4 -week treatment period. In this study, clinically 
meaningful treatment effects were observed for both dasotraline 4  mg/day and 8 mg /day 
compared to placebo. For the primary efficacy endpoint, change from baseline in ADHD Rating Scale Version IV  (ADHD RS -IV) with adult prompts total score at week  4, statistical 
significance was achieved for dasotraline 8  mg/day compared to placebo (adjusted p = 0.019) 
with a strong trend for dasotraline 4 mg /day (adjusted p = 0.076). Efficacy with both doses was 
observed for the secondary endpoint Clinical Global Impression ‚ÄìSeverity of Illness  (CGI -S; 
4 mg  group p = 0.021; 8 mg  group p = 0.013). A dose response relationship was observed 
supporting pharmacological activity in ADHD. Decreases in 3,4-dihydroxyphenylglycol ( DHPG) 
concentrations indicated the presence of central NET inhibition. Adverse events (AEs) were 
consistent with dasotraline pharmacology, ie, insomnia, decreased appetite, dry mouth, and 
headache. Worsening of insomnia associated with dasotraline was characterized by [CONTACT_2695], and 
shifts in Insomnia Severity Index (ISI) total score, particularly with dasotraline 8  mg/day. AEs, 
particularly insomnia, were the most frequent reason for discontinuation of dasotraline 8 mg /day. 
Decreases in mean body weight were generally greater for dasotraline 8  mg/day than 4 mg /day. 
Increases in mean supi[INVESTIGATOR_29909]-up were generally higher on dasotraline 8 mg /day than 4 mg /day 
 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  26 19 November 2017 SEP360-301 
The second adult study (SEP360- 301) evaluated the efficacy and safety of dasotraline (4  mg/day 
and 6 mg/day) and although the doses were found safe, and the [ADDRESS_29161] study (SEP360-304) showed that dasotralin e, flexibly dosed from 4 mg/day to 
8 mg/day , appeared to be safe, well tolerated, and effective in adults for the long term treatment 
of ADHD. Given the long half-life of dasotraline, dosing increments at a frequency of no more than every [ADDRESS_29162] been assessed in several studies.  
One study was completed that evaluated the safety, tolerability, pharmacokinetic, and 
pharmacodynamic properties of dasotraline in ped iatric (6 ‚Äì 12 years) and adolescent 
(13 - 17 years) subjects  with ADHD. In this multicenter, open-label study 105 subjects were 
assigned to single oral doses of dasotraline 1 - 16 mg in a dose- escalating manner. Dasotraline 
was characterized by [CONTACT_29943] (median t
max was 9.6 to 12 hour s) and elimination (median 
t¬Ω was 56 to 84 hours) in both pediatric and adolescent subjects. The change in C max with dose 
was slightly greater than dose proportional. Increase in overall exposure (AUC) with dose was 
greater than dose proportional. Apparent oral clearance was highest in the lowest dose group 
relative to the higher dose groups. No deaths, serious adverse events (SAE), or discontinuations 
because of an adverse event (AE) were reported in this study. The mos t frequently reported AE 
by [CONTACT_29944] (25  subjects; 23.8%) and electrocardiogram QT prolonged 
(5 subjects; 4.8%), nearly all of which were considered related to study drug and mild in 
severity. Tachycardia AEs were reported in both age groups and in every dose cohort. Most 
events of tachycardia were reported on the day of study drug administration. No subjects 
experienced QT prolongations > 500 msec. Based on the centrally read electrocardiogram 
(ECGs ) in the study, no clinically signif icant trends were identified within the ECG results.  
Blood pressure increased, blood pressure systolic increased, blood pressure orthostatic abnormal, and orthostatic hypotension AEs were reported in [ADDRESS_29163] each. Overall, after dosing, 90 subjects (85.7%) met predefined criteria for orthostatic tachycardia and 40  (38.1%) met 
predefined criteria for orthostatic hypotension. 
Two studies have been  completed to support dasotraline as a compound with minimal abuse 
potential.  The first study  (SEP360-201), a randomized, double-blind, parallel-group, outpatient 
study at 30 sites , evaluated the efficacy and safety of dasotraline in adults with ADHD using 
2 doses (4 mg /day or 8  mg/day) versus placebo over a 4- week treatment period.  No signs or 
symptoms of withdrawal upon discontinuation of dasotraline were observed for either dose. In 
addition, there was no evidence of drug liking or deterioration of psychiatric symptoms 
associated with either dose of dasotraline. No misuse or diversion of dasotraline was detected through the abuse potential monitoring plan. A second study evaluated dasotraline‚Äôs abuse 
liability and was conducted in recreational stimulant users; results indicated that dasotraline has 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  27 19 November 2017 low abuse liability  (Koblan-2016). All doses of dasotraline (8, 16, 36 mg ) demonstrated 
significantly lower drug liking scores than methylphenidate (40, 80 mg ) and were no greater than 
placebo.  
Four previous clinical studies in healthy adult subjects using single doses ranging from 0.2 mg  to 
36 mg  and doses of 1 mg /day to  3 mg /day for durations up of 21 days, and another study in adult 
subjects with major depressive disorder (MDD) using doses of 0.5 mg /day and 2 mg /day for up 
to 8 weeks (56  days) also have been completed. In these clinical studies, dasotraline was 
generall y safe and well tolerated at the doses studied and there was no evidence of abuse or 
diversion and no symptoms of withdrawal. 
4.4. Hypothesis  
This study is designed to test the superiority of dasotraline 2 mg/day against placebo  based on 
Swanson, Kotkin, A gler, M-Flynn, and Pelham Scale ( SKAMP )-Combined score in pediatric 
subjects  aged 6 -12 years  with ADHD who weigh ‚â§ 30 kg. 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  28 19 November 2017 5. STUDY OBJECTIVES  
5.1. Primary Objectives  
The primary objective is to evaluate the efficacy of dasotraline 2 mg/day  compared to placebo on 
attent ion-deficit hyperactivity disorder (ADHD) symptoms in children (6  - 12 years of age) in a 
laboratory classroom setting as measured by [CONTACT_29945]  15 in SKAMP 
Combined Score. 
5.2. Secondary Objectives  
The secondary objectives of the study are: 
‚Ä¢ To evaluate the efficacy of dasotraline compared to placebo on ADHD symptoms 
throughout the day (12 to 24 hours postdose) in children in a laboratory classroom setting 
as measured by [CONTACT_29946]. 
‚Ä¢ To evaluate the safety and tolerabil ity of dasotraline using physical examinations, 12- lead 
electrocardiograms (ECG), vital signs, adverse event (AE) reports, clinical laboratory results, and Columbia ‚Äì Suicide Severity Rating Scale ( C-SSRS) Children‚Äôs Assessment.  
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  29 19 November 2017 6. STUDY ENDPOINTS  
6.1. Primary End points  
The primary endpoint is change from baseline at Day 15 in ADHD symptoms as measured by 
[CONTACT_29947] -Combined score obtained from an average of the 7 assessments collected across 
the 12-hour classroom day (12 to 24 hours postdose). 
6.2. Secondary Endpoints  
The secondary endpoints are:  
‚Ä¢ Mean SKAMP -Combined score from the 7 assessments collected across the 12 -hour 
classroom day (12 to 24 hours postdose) on Day  15 
‚Ä¢ SKAMP -Combined score at each of the assessment times (12 -, 14-, 16-, 18-, 20-, 22-, 
and 24-hours postdose) during the classroom day on Day  15 
‚Ä¢ Change from baseline at Day 15 in SKAMP-Combined score at each of the 
assessment times (12 -, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the 
classroom day 
‚Ä¢ Change from baseline at Day 15 in mean SKAMP- Attention subscale score obtained 
from the 7  assessments collected across the 12 -hour classroom day (12 to 24 hour s 
postdose) 
‚Ä¢ SKAMP -Attention subscale score at each of the assessment times (12 -, 14-, 16-, 18-, 
20-, 22-, and 24-hours postdose) during the classroom day on Day  15 
‚Ä¢ Change from baseline at Day 15 in SKAMP- Attention subscale score at each of the 
assessment times (12 -, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the 
classroom day 
‚Ä¢ Change from baseline at Day 15 in mean SKAMP-Deportment subs cale score 
obtained from the 7 assessments collected across the 12 -hour classroom day 
(12 to 24 hours postdose) 
‚Ä¢ SKAMP -Deportment subscale score at each of the assessment times (12 -, 14-, 16-, 
18-, 20-, 22-, and 24-hours postdose) during the classroom day on Day  15 
‚Ä¢ Change from baseline at Day 15 in SKAMP- Deportment subscale score at each of the 
assessment times (12 -, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the 
classroom day 
‚Ä¢ Change from baseline at Day [ADDRESS_29164] Measure of Performance 
(PERMP )-Attempted and Correct Problems scores at each of the assessment times 
(12-, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day 
‚Ä¢ PERMP -Attempted and Correct Problems scores at each of the assessment times (12 -, 
14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day on Day  15 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  30 19 November 2017 ‚Ä¢ Change from baseline at Day 15 in mean PERMP -Attempted  score obtained from an 
average of the 7  assessments collected across the 12 -hour classroom day (12 to 
24 hours postdose). 
‚Ä¢ Change f rom baseline at Day [ADDRESS_29165] score obtained from an 
average of the 7  assessments collected across the 12 -hour classroom day (12 to 
24 hours postdose). 
‚Ä¢ The incidence of overall AEs, serious AEs (SAEs), and AEs (or SAEs) leading to 
discontinuations 
‚Ä¢ Absolute values and change from baseline in clinical laboratory evaluations (serum 
chemistry, hematology, and urinalysis) 
‚Ä¢ Absolute values and changes from baseline in vital signs, body weights, and 12- lead 
ECGs  
‚Ä¢ Frequency and severity of suicidal ideation and suicidal behavior as assessed by [CONTACT_941] C-SSRS  
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  31 19 November 2017 7. INVESTIGATIONAL PLAN  
7.1. Overall Study Design  
This is a randomized, double-blind, placebo-controlled, parallel -group, efficacy and safety  study, 
in pediatric subjects  with ADHD in a laboratory classroom set ting. The study will target 
100 subjects ( 50 per treatment group ) to complete the study. The study will be comprised of 
3 periods: Period 1: screening (up to 35 days) including a 3 - 5 day ADHD medication washout, 
if necessary,  prior to Day  -1; Period  2: double-blind randomized treatment with either dasotraline 
(2 mg /day) or placebo for 14 days; and Period 3: End of Study (EOS) visit ([ADDRESS_29166] 
dose). Prior to the start of treatment (Day 1) and following  the conclusion of the 14- day double-
blind per iod (Day 15), subjects will undergo a full-day laboratory classroom evaluation during 
which up to [ADDRESS_29167] (Permanent 
Product Measure of Performance [PERMP])  will be administered to evaluate sustained attention 
and effort . The appropriate math level  for each subject is determined based on results of the math  
pretest administered at screening.  
The p rimary efficacy endpoint will be baseline to endpoint change in the SKAMP -Combined 
score. 
Safety  and tolerability  will be  monitored throughout the study by [CONTACT_29948] s, 12- lead ECG,  vital signs,  AEs, clinical  laboratories  (hematology, chem istry, and 
urinalysi s), and C- SSRS. A Data and Safety Monitoring Board (DSMB) will review safety and 
clinical outcome data including data on AEs and serious AEs at re gular intervals.  
Screening: The screening period will be completed within a maximum of [ADDRESS_29168]‚Äôs parents/legal guardians.  
Subjects will be confirmed as meeting DSM -5 criteria for a diagnosis of ADHD. Subjects may 
be currently untreated for ADHD or receiving a  treatment regimen of stimulant medication for 
ADHD at Screening. On Day  -7 the ADHD Rating S cale Version  IV - Home Version (modified 
for investigator administration) ( ADHD -RS-IV HV) will be completed and subjects will attend a 
half-day practice laboratory classroom session intended to familiarize them with classroom schedules 
and procedures relat ed to SKAMP evaluations, PERMP tests, and other planned activities. Any 
subjects receiving stimulant medication for ADHD will discontinue that ADHD treatment for [ADDRESS_29169]‚Äôs parent/legal guardian will be contact[CONTACT_29949] . Clinically significant is defined a s an ADHD -RS-IV HV 
total score ‚â•  26. Subjects who do not demonstrate clinically significant symptoms on Day -1 will 
be considered screen failures and will not be eligible for randomization. 
Subjects may be rescreened a maximum of 2 times for out of range c linical laboratory results, 
insufficient medication washout periods, etc. 
3URWRFRO6(39HUVLRQ  'DVRWUDOLQH
&RQILGHQWLDODQG3URSU LHWDU\  1RYHPEHU'RXEOHEOLQG3HULRG 2Q'D\VXEMHFWVZLOOUHWXUQWRWKHFOLQLFLQWKHPRUQLQJDQG WKRVHPHHWLQJ
DOOLQFOXVLRQDQGQRH[FOXVLRQFULWHULDZLOOEHUDQGRPL]HG WRUHFHLYHPJGD\GDVRWUDOLQH RU
SODFHERDQGZLOODWWHQGF ODVVURRPVHVVLRQVL QZKLFKWKH\ZLOO EHHYDOXDWHGIRU$'+'
V\PSWRPVXVLQJWKH6.$03DVVHVVP HQW'XULQJWKLVEDVHOLQHFODVV URRPDVVHVVPHQW'D\
VXEMHFWVZLOOEHHYDOXDWHGDWUHJXODULQWHUYDOVDSSUR[LPDWHO\ $0$03030
3030DQG306XEMHFWVZ LOOEHJLQWDNLQJVWXG\GUXJRQWKHHYHQLQJRI'D\ZLW KRU
ZLWKRXWIRRGDIWHUWKHILQDO 30EDVHOLQHFODVVURRPDVVHV VPHQW6XEMHFWVZLOOWDNHRQH GRVH
HDFKHYHQLQJEHIRUHEHG WLPHIRUDWRWDORIGD\V6WXG\GUXJ VKRXOGEHWDNHQDWD SSUR[LPDWHO\WKH
VDPHWLPHHDFKHYHQLQJ7KHILUVWGRVHRIVWXG\GUXJPD\EHDGP LQLVWHUHGLQWKHFOLQLFDIWHUDOO
DVVHVVPHQWVDUHFRPSOHWHGDQGEH IRUHWKHVXEMHFWOHDYHVRUDW KRPH2QWKHQLJKW'D\EHIRUH
WKHVHFRQGFODVVURRPGD\VWXG\GUXJ PXVWEHWDNHQDWDSSUR[LPD WHO\30SOXVRUPLQXVPLQXWHV
'XULQJWKHGRXEOHEOLQGSHULRGWKH FOLQLFDOVLWHZLOODWWHPSW WRFRQWDFWWKHVXEMHFW¬∂VSDUHQWOHJDO
JXDUGLDQGDLO\ZLWKD UHPLQGHUWRDGPLQLVWHUVWXG\GUXJ$GRVL QJGLDU\ZLOOEHSURYLGHGWRWKH
SDUHQWOHJDOJXDUGLDQWRUHFRU GWKHGDWHDQGWLPH RIHDFKDGPLQ LVWUDWLRQRIVWXG\GUXJ2Q'D\
VXEMHFWVZLOOUHWXUQWRWKHFOLQ LFLQWKHPRUQLQJDW$0DQ GFODVVURRPVHVVLRQVZ LOOEHVWDUWHGDW
DSSUR[LPDWHO\$0$03 0303030DQG30WR FRLQFLGHZLWK
DQGKRXUVIROORZLQJWKH'D\GRVH
(QGRI6WXG\ 6HYHQ¬ìGD\VDIWHUWKHODVW GRVHRIVWXG\GUXJDOOVXEMHFWV ZLOOUHWXUQWRWKH
FOLQLFDQGFRPSOHWHDVVHVVPHQWV $IWHUWKH(26YLVLWDOOVXEMH FWVZLOOEHUHIHUUHGIRU
FRQWLQXDWLRQRIWKHLUF DUHDVGHWHUPLQHGE\WKHLQYHVWLJDWRU$ GGLWLRQDOO\IRUVXEMHFWVZKR
FRPSOHWHWKHVWXG\RUGLVFRQWL QXHIRUWROHUDELOLW\RUODFNRIH IILFDF\UHDVRQVWKHVSRQVRUZLOO
SURYLGHVXSSRUWIRUDSSURYHG$'+' PHGLFDWLRQFRVWVIRUXSWR PRQWKVDIWHUSDUWLFLSDWLRQLQ
WKHVWXG\LIGHHPHGPHGLFDOO\ DSSURSULDWHE\WKHVXEMHFW¬∂VKHD OWKFDUHSURYLGHU 
$VWXG\VFKHPDWLFLVSUHVHQWHGL Q)LJXUH'HWDLOVRIWKHVWXG \DVVHVVPHQWVDQGRWKHU
SURFHGXUHVWREHSHUIRUPHGDW HDFKYLVLWDUHSUHVHQWHGLQ 7DEOH6FKHGXOHRI$VVHVVPHQWVDQG
6HFWLRQ 6WXG\$VVHVVPHQWV,IQHFHVVD U\VXEMHFWVPD\UHWXUQWRWKHF OLQLFDWDQ\WLPHIRUDQ
XQVFKHGXOHGYLVLW7KHWLPLQJRIH YHQWVGXULQJDVDPSOHODERUDW RU\FODVVURRPGD\LVSURYLGHGLQ
7DEOHZLWKDGGLWLRQDOGHWD LOVSURYLGHGLQWKH/DERUDWRU\&ODVVURRP0 DQXDO
)LJXUH 6WXG\6FKHPDWLF


Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  33 19 November 2017 7.2. Treatment Assignment and Blinding  
7.2.1. Treatment Assignment  
After successfully meeting study entry criteria, subjects will be randomly assigned in a 1:1  ratio 
to 1 of the followi ng treatments:  
‚Ä¢ 2 mg /day d asotraline (N  = 50 subjects)  
‚Ä¢ Placebo (N  = 50 subjects)  
An Interactive Response System (IXRS) will be used to manage randomization on Day  1 and, if 
necessary, for emergency unblinding (see Section  7.2.3) of treatment assignment during the 
study. The IXRS is an integrated web based subject and drug management system. 
Study medication will be assigned by [CONTACT_29950]. The IXRS 
will generate instructions on which  medication  number to assign to a subject. 
7.2.2. Blinding  
This is a double-blind study. All study drug capsules (both dasotraline and placebo) are identical 
in color, shape, size, and packaging in order to maintain the blind. 
Subjects, Sponsor personnel, Investigator staff, persons performing the assessments, clinical 
operations personnel, data analysts, and personnel at central laboratories will remain blind to the identity of the treatment from the time of randomization until database lock and unblinding, 
using the following methods; (1)  randomization data are kept strictly confidential until the time 
of unblinding, and will not be accessible by [CONTACT_29951] s tudy with the exception 
of Data and Safety Monitoring Board (DSMB) members involved in re gular review of safety 
data, and Clinical Trial Materials Management personnel , (2) the identity of the treatments will 
be concealed by [CONTACT_29952], labeling, schedule of 
administration, and appearance. 
7.2.3. Emerge ncy Unblinding Procedures  
The IXRS will be used, if necessary, for emergency unblinding of treatment assignment during 
the study. The blinded dose information is to be broken only in an emergency when knowledge of such treatment may have an impact on further treatment decisions or aid in the emergency 
treatment of the subject. Any subject for whom the blind is broken is to be discontinued from 
receiving any additional study drug and should undergo early termination procedures as described in Section  14. 
7.3. Rationale  
7.3.1. Rationale for the Study Design 
The current study is a randomized, double-blind, placebo-controlled, parallel-group, laboratory 
classroom study in pediatric subjects with ADHD  weighing ‚â§ [ADDRESS_29170] of dasotraline ( 2 mg /day) compared with placebo 
over an entire day in a simulated  classroom setting. The laboratory school protocol is a 
particularly useful method for evaluation of efficacy in subjects with ADHD because it 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  34 19 November 2017 represents a controlled study setting for evaluation and comparison of study treatments and is 
designed to mimic a typi[INVESTIGATOR_29908]. 
7.3.2. Rationale for the Dosages 
The dosage of 2 mg /day of dasotraline w as selected to evaluate dasotraline safety , tolerability,  
and efficacy within the dose range being evaluated in the ongoing studies in pediatric subjects 
with ADHD. 
A dasotraline 2 mg /day dose is  expected to produce mg/kg exposures in pediatric subjects 
weighing ‚â§ [ADDRESS_29171] a diagnosis of ADHD 
established by a comprehensive psychiatric evaluation that reviewed Diagnostic and  Statistical 
Manual for Mental Disorders, Fifth Edition (DSM- 5) criteria for ADHD (inattentive, 
hyperactive, or combined presentation); diagnosis will be confirmed using the Schedule for Affective Disorders and Schizophrenia for School- Age Children Present  and Lifetime Version 
(K-SADS -PL). Subjects are required to weigh ‚â§ 30 kg since a 2  mg/day dose in such a group is 
expected to have mg/kg exposures similar to those demonstrated to be effective in children and 
adults. 
7.3.4. Rationale for the Endpoints 
The primary efficacy measure (mean SKAMP -Combined Score) is a widely accepted efficacy 
endpoint intended to assess functional impairment related to ADHD and has been used in many 
laboratory classroom studies in children ( Childress-2015, Wigal -2014).  
7.4. Prevention of Missing Data  
In an effort to minimize the number of subjects who are terminated from the study prior to study 
completion, the following study design and conduct elements are implemented; (i) use of clinical 
sites with a good track record of having performed this type of study, (ii) training provided to the 
clinical sites o n the importance of the informed consent/assent process and ensuring subjects and 
their parent/guardian understand the commitment they are making, including the intent to 
complete the trial, and (iii)  monitoring data collection for adherence during the study.  
Protocol SEP360-311, Version 3.[ADDRESS_29172] weighs ‚â§ [ADDRESS_29173]‚Äôs parents /legal guardian s must give written informed consent, 
including privacy authorization, prior to study participation. The subject will provide 
informed assent prior to study participation. 
4. Subject meets Diagnostic and Statistical Manual of Mental Disorders Fifth Edition 
(DSM -5) criteria for a primary diagnosis of ADHD (inattentive, hyperactive, or 
combined presentation) at screening established by a comprehensive psychiatric 
evaluation that reviews DSM- 5 criteria and confirmed using the Schedule for Affective 
Disorders and Schizophrenia for School- Age Children -Present and Lifetime version 
(K-SADS -PL) at screening.  
5. Subject is currently either untreated for ADHD or receiving  a treatment regimen of a 
stimulant medication prescribed as monotherapy (i.e., methylphenidate, mixed amphetamine salts, lisdexamphetamine, or dextroamphetamine)  within th e approved 
labeled dose range for ADHD.  
6. In the opi[INVESTIGATOR_871], the subject is not treatment refractory . 
7. Any subject not receiving ADHD medication at screening must display  clinically 
significant ADHD symptoms, as measured  by [CONTACT_29953]- RS-IV scor e ‚â• [ADDRESS_29174] be well tolerated and clinically effective based on clinical assessment and informant 
interview, as well as, review of available medical  records. Note: The ADHD Rating Scale 
Version  IV - Home Version (modified for investigator administration) ( ADHD- RS-IV 
HV) will be administered at Screening by [CONTACT_29954].  
9. Subject is male or a non -pregnant, non- lactating  female.  
10. Subject, if female, must not be pregnant or breastfeeding, and if ‚â• [ADDRESS_29175] practice true abstinence (consistent with lifestyle) and must 
agree to remain abstinent or agree to use an effective and medically acceptable form of 
birth control, from the time of informed consent/assent to at least [ADDRESS_29176] be in general good health (defined as the absence of any clinically relevant 
abnormalities as determined by [CONTACT_093]) b ased on screening physical and 
neurological examinations, medical history, and clinical laboratory values (hematology, chemistry, and urinalysis). Note: If any of the hematology, chemistry, or urinalysis results are not within the laboratory‚Äôs reference range, then the subject can be included only if 
the investigator determines the deviations to be not clinically relevant.  
13. Subject is within the 3rd to 97th percentile for gender specific weight -for-age from the 
Centers for Disease Control and Prevention (CDC ) growth charts. See Section s 24, 
and 25, Appendix V and VI for growth chart s. 
14. Subject must report a history of being able to swallow capsules. 
15. Subject and subject‚Äôs parent/legal guardian must be able to fully comprehend the informed consent/assent forms, understand and be willing and able to comply with all 
study procedures and visit schedule, and be able to communicate satisfactorily with the investigator and study coordinator. 
16. Subject , on Day -1, has evidence of clinically significant ADHD symptoms as measured 
by [CONTACT_29953] -RS-IV HV total score ‚â• 26. If subject has been receiving stimulant 
pharmacotherapy  for ADHD the ADHD- RS-IV should be administered following a 
minimum 72-hour washout from prior ADHD medication treatment.  
8.2. Subject Exclusion Criteria  
The subjects who meet any of the following criteria will be excluded  from  the study 
1. Subject or parent/legal guardian has commitments during the study that  would interfere 
with attending study visits.  
2. Subject is currently being treated for ADHD with a non- stimulant product, or has been 
treated with a non -stimulant product in the [ADDRESS_29177] has failed 2  adequate courses (dose and duration) of stimulant or non- stimulant 
treatment for ADHD . 
4. Subject is considered treatment refractory, as judged by [CONTACT_093]. 
5. Subject currently has a diagnosis of asthma that has required daily treatment with bronchodilators or nebulizer treatments in the 30 day s prior to screening and/or who may 
require daily treatments with these agents over the course of the trial. Intermittent use of 
bronchodilators is not exclusionary. Subjects who have a history of requiring persistent 
asthma treatment should be discusse d with the medical monitor prior to randomization . 
6. Subject has any clinically significant unstable medical abnormality, chronic disease, or a 
history of a clinically significant abnormality of the cardiovascular, gastrointestinal, 
respi[INVESTIGATOR_696], hepatic, or renal systems, or a disorder or history of a condition (eg, malabsorption, gastrointestinal surgery) that may interfere with drug absorption, 
distribution, metabolism, or excretion. Note: Active medical conditions that are minor or 
well-controlled are not exclusionary if they do not affect risk to the subject or the study 
results. In cases in which the impact of the condition upon risk to the subject or study 
results is unclear, the medical monitor should be consulted. Any subject with a known 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  37 19 November 2017 cardiovascular disease or condition (even if controlled) must be discussed with the 
medical monitor during screening. 
7. Subject has a history or presence of abnormal ECGs, which in the investigator‚Äôs opi[INVESTIGATOR_29910]. Screening site ECGs will be centrall y over -read, and eligibility 
will be determined by [CONTACT_29955]-read report. 
8. Subject has any diagnosis of bipolar I or II disorder, major depressive disorder, conduct 
disorder, obsessive-compulsive disorder, any history of psychosis, autism spectrum disorder, disruptive mood dysregulation disorder (DMDD), intellectual disability, 
Tourette‚Äôs Syndrome, confirmed genetic disorder with cognitive and/or behavioral 
disturbances. Note: Subjects with oppositional defiant disorde r (ODD) are permitted to 
enroll in the study as long as ODD is not the primary focus of treatment.  
9. Subject has a first-degree relative (biological parent or sibling) with a history of 
schizophrenia, schizoaffective disorder, bipolar I disorder, or bipolar II disorder. 
10. Subject has generalized anxiety disorder or panic disorder that has been the primary focus 
of treatment at any time during the [ADDRESS_29178] has evidence of any chronic disease of the central nervous system (CNS) such as tumors, inflammation, seizure disorder, vascular disorder, potential CNS related disorders 
that might occur in childhood (eg, Duchenne Muscular dystrophy, myasthenia gravis, or other neurologic or serious neuromuscular disorders). 
12. Subjects with a  history of persistent neurological symptoms attributable to serious head 
injury. 
13. History of febrile seizure, drug-induced seizure, or alcohol withdrawal seizure is 
exclusionary.  
14. Subject s taking anticonvulsants for seizure control currently or within the past [ADDRESS_29179] has uncontrolled thyroid disorder as evidenced by  [CONTACT_21923] 
(TSH) ‚â§ 0.8 x the lower limit of normal ( LLN ) or ‚â• 1.25 x the upper limit of normal 
(ULN ) for the reference laboratory . 
16. Subject answers ‚Äúyes‚Äù to ‚ÄúSuicidal Ideation‚Äù item  4 (active suicidal ideation with some 
intent to act, without specific plan) or item 5 (active suicidal ideation with specific  plan 
and intent) for any lifetime history on the C-SSRS Children‚Äôs Lifetime/Recent 
assessment at screening.  
17. Subject has any history of attempted suicide  or clinically significant suicidal ideation , in 
the opi[INVESTIGATOR_871]. 
18. Subject has a history of severe allergies to more than [ADDRESS_29180] has history of intolerance (safety) or lack of efficacy to stimulants. 
20. Subject has taken any antipsychotic medication within [ADDRESS_29181] has taken any herbal and/or complementary treatments, eg , St. John‚Äôs Wort, 
within  [ADDRESS_29182]  has taken  any antidepressant medication (eg, bupropi[INVESTIGATOR_2394], selective serotonin 
reuptake inhibitor [SSRI]/ serotonin norepi[INVESTIGATOR_26331] [SNRI], tricyclic, 
etc) within  [ADDRESS_29183] has ever taken any monoamine oxidase [MAO] inhibitor at any time . 
24. Subject is currently undergoing ongoing or newly initiated Cognitive Behavioral Therapy (CBT) for the treatment of ADHD; behavioral therapi[INVESTIGATOR_014], including school based 
interventions that were initiated less than one month prior to screening; or, behavioral therapy that in the opi[INVESTIGATOR_29911]‚Äôs ability to participate for the duration of the study. School based interventions that have been in 
place for more than one month prior to screening will be allowed.  Note: Unavoidable 
changes in school-based interventions that occur during study participation will not be 
exclusionary, but should be documented by [CONTACT_093], to the extent possible. 
Subjects should not be enrolled who, in the judgment of the investigator, are expected to 
start substantially different or more intensive course of behavioral therapy over the duration of their participatio n in the study. 
25. Subject or subject‚Äôs family anticipates a move outside the geographic range of investigative site during the study period, or plans extended travel inconsistent with the recommended visit interval during study duration. 
26. Subject has history of, or current, malignancy  other than non-melanomatous skin cancer. 
27. Subject has history of posi tive test for Hepatitis  B surface antigen or Hepatitis  C 
antibody. 
28. Subject is known to have tested positive for human immunodeficiency virus (HIV). 
29. Subject has participated in a classroom study within 6 months prior to the start of screening or has participated in any other clinical  study with an investigational 
drug/product within [ADDRESS_29184] shows evidence of substance or alcohol use or is currently using tobacco or other 
nicotine-containing products, or has a positive urine drug screen (UDS) at screening. Note: Subjects with a positive UDS may be allowed to continue in the study, provided that the investigator determines that the positive test is as a result of ta king medic ations 
as prescribed  after consultation with the medical monitor . 
31. Subject is taking any disallowed medications for chronic treatment.  
32. Subject has previously been enrolled in a clinical trial of dasotraline ( SEP-225289). 
33. Subject‚Äôs parent/legal guardian is an investigational site staff member or the relative of an investigational site staff member.  
34. Subject is, in the opi[INVESTIGATOR_871], unsuitable in any other way to participate in 
this study.  
Protocol SEP360-311, Version 3.[ADDRESS_29185] ‚Äôs sibling or family member living in th e same household is participating in the 
same laboratory classroom cohort  for this study. 
36. Subject is u nable to perform at the basic level of the standardized math test as defined in 
the laboratory classroom manual. 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  40 19 November 2017 9. STUDY DRUG MATERIALS  AND MANAGEMENT  
9.1. Descr iption of Study Drug 
The study medication is described in Table 6. 
Table 6: Investigational Product 
Attribute  Investigational Product  
Product name  [CONTACT_30007] 2 mg Matching Placebo  
Dosage f orm Capsules  Capsules  
Unit dose  One capsule  One capsule  
Route of administration  Oral Oral 
Physical description  Swedish orange, size #4  Swedish orange, size #4  
 
In addition to dasotraline, the active ingredient, each capsule contains: Mannitol United St ates 
Pharmacopeia (USP), Sodium Starch Glycolate NF, Talc USP, and Magnesium Stearate NF.  
The matching placebo capsule is identical to dasotraline in color, shape, size, and packaging and 
contains all ingredients, except the active dasotraline.  
9.2. Study Drug Packaging and Labeling  
9.2.1. Package Description  
Study drug will be provided in 1 week blister cards containing 10 capsules of dasotraline 2 mg  or 
placebo capsules (7  days + 3 extra days).  
9.2.2. Labeling Description   
All packaging for the s tudy drug will be labeled with: 
‚Ä¢ Protocol number 
‚Ä¢ Sponsor‚Äôs name [CONTACT_3816] 
‚Ä¢ Content (eg number of capsules ) 
‚Ä¢ Investigational New Drug statement  
‚Ä¢ Instructions for use and storage 
‚Ä¢ Blank space for subject identifiers  
‚Ä¢ Batch  number 
‚Ä¢ Unique medication number 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  41 19 November 2017 9.3. Study Drug Storage  
All study medica tion should be stored at USP Controlled Room Temperature: 20¬∞C - 25¬∞C 
(68¬∞F - 77¬∞F); excursions permitted to 15¬∞C - 30¬∞C (59¬∞F - 86¬∞F). The subject‚Äôs parent(s)/legal 
guardian(s) will be instructed to store the study medication at room temperature.  
In addit ion, the subject‚Äôs parent(s)/legal guardian(s) will be instructed to store the study 
medication in a location where it cannot be inadvertently accessed and consumed by [CONTACT_29956]‚Äôs access.  
9.4. Dispensin g of Study Drug 
An Interactive Response System (IXRS) will be used to manage subject screening and 
enrollment. The IXRS is an integrated web- based subject and drug management system.  Specific 
User Manuals will be supplied. 
Study medication blister cards will be assigned by [CONTACT_29957]. 
The IXRS will generate instructions on which medication number to assign to a subject. Appropriate guidelines should be followed in proper dispensation to the study participant. Each 
subject will be dispensed two [ADDRESS_29186]‚Äôs parent/legal guardian, subjects will self- administer the 
study drug on an outpatient basis (see Section  10.1 ). The daily dosage (one capsule) will be 
clearly labeled on the study drug blister card.  
9.5. Study Drug Accountability  
The Investigator or designee is responsible for storing the drug in a secure location and for maintaining adequate records of drug disposition that includes the dates, quantity, and use by 
[CONTACT_1766]. If the study is stopped for any reason or completed, all unused supplies of drug will be returned to the Sponsor, unless other instructions are provided in writing by [CONTACT_2728]/ clinical 
research organization ( CRO ). 
Upon receipt of clinical trial material (CTM) the Principal Investigator, or designee, will 
inventory the supplies and verify receipt of supplies. The site will send an Acknowledgement of 
Receipt to Sunovion Pharmaceuticals, or designee, confirming date of receipt, inventory, and 
condition of CTM received. 
The Investigator, or designee, agrees to collect and document all used and unused study 
medication fr om study subjects/parent s/legal guardian s at appropriate study visits. 
Study drug will not be dispensed to any person who is not a study subject under this protocol. 
On Day  1 a dosing diary will be provided to the parent/legal guardian to record the date a nd time 
of each administration of study drug. On Day 15 the parent/legal guardian will bring the dosing 
diary  to the visit.  Only the date and time of the Day  [ADDRESS_29187] will be supplied by [CONTACT_16049]/CRO. The Investigator or designee on 
an ongoing basis must maintain a drug inventory record of supplied, received, dispensed, and 
returned study drug. The Investigator or designee is required to return all unused supplies of 
study drug as well as empty packaging from used study drug to the Sponsor or designee as 
instructed. The Investigator or designee is required to maintain copi[INVESTIGATOR_29912], drug accountability records, and records of return or final disposal of the s tudy drug  in 
accordance with local regulatory requirements . 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  43 19 November 2017 10. TREATMENT OF SUBJECTS 
10.1. Study Medication  
As described in Section  7.2.1, subjects will be randomized to 1 of 2 treatments ( 2 mg /day 
dasotraline or placebo). 
Under supervision from the subject‚Äôs parent/legal guardian, subjects will self- administer the 
study drug on an outpatient basis for [ADDRESS_29188]; the active ingredient is 
an ocular irritant.  
10.2. Treatment Compliance  
During the double- blind period, the clinical site will attempt to contact [CONTACT_29320]‚Äôs parent/legal 
guardian dai ly with a reminder to administer study drug.  
The Investigator will record the dose of the study drug and the dates of the initial and final 
administration  for each  dose. 
Compliance with study drug will be monitored closely and determined at each visit. Subjects and their parent(s)/legal guardian(s) will be instructed to b ring all unused study drug with them to the 
Day 15 visit. Compliance will be assessed by [CONTACT_29958] (per capsule count) by [CONTACT_29959] a visit period and multiplying by 100. Subjects who miss more than 25% of scheduled doses or 
take more than 125% of the scheduled doses will be considered noncompliant. Evidence of 
noncompliance must be immediately reported to the Medical Monitor. Potential noncompliance will be  discussed with subjects and their parent(s)/legal guardian(s), and at the investigator‚Äôs 
discretion may result in termination of the subject from the study. All subjects and their parent(s)/legal guardian(s) will be reminded of the importance of strict compliance with taking study drug for the effectiveness of treatment and for the successful outcome of the study. 
10.3. Concomitant Medications and Therapi[INVESTIGATOR_29913]/assent  and the 
EOS v isit or at  discontinuation will be recorded  on the CRF:  Medication  name, dose, frequency, 
route, start date, stop date, and indication. 
All medications will be coded using World Health Organization drug dictionary ( WHO- DD). 
Information on the format and version of the coding dictionary will be provided in the Data 
Management Plan (DMP).  
Protocol SEP360-311, Version 3.[ADDRESS_29189] taken any of the following m edications within the timeframe listed:  
‚Ä¢ Anticonvulsants for seizure control within 2 years prior to screening 
‚Ä¢ Antipsychotic medication within 6  months prior to screening 
‚Ä¢ Herbal or complementary treatments, eg , St. John‚Äôs Wort, within 6 months prior to 
Day 1 
‚Ä¢ Any antidepressant medication (eg, bupropi[INVESTIGATOR_2394], SSRI/ SNRI, tricyclic, etc) within 
6 months prior to Day  1 
‚Ä¢ MAO inhibitor at any time  
‚Ä¢ Non-stimulant product as treatment for ADHD with in [ADDRESS_29190] dose of study drug. 
Use of any of the following medications is not permitted during the study from screening 
through the EOS visit: 
‚Ä¢ Lithium (any lithium preparation or formulation)  
‚Ä¢ Alpha-2 adrenergic receptor agonists (including clonidine and guanfacine), modafinil, armodafinil, atomoxetine, or any non- stimulant class agent  
‚Ä¢ Antidepressant  medications (eg, bupropi[INVESTIGATOR_2394], SSRI/SNRI, MAO inhibitor , tricyclic, 
etc) 
‚Ä¢ Anticonvulsant medications (eg, phenytoin, carbamazepi[INVESTIGATOR_050], lamotrigine, valproic acid, etc) and antipsychotic medications  
‚Ä¢ Pseudoephedrine- containing medications  
‚Ä¢ Medications with significant effect on blood pressure or heart rate. Intermittent use of 
asthma treatments is permitted but should be discussed with the medical monitor.  
‚Ä¢ Sleep  aids with the exception of melatonin  
‚Ä¢ Diphenhydramine except topi[INVESTIGATOR_29899] 
‚Ä¢ Herbal or complementary  treatments, eg , St. John‚Äôs Wort  
‚Ä¢ CYP2B6 substrates or inhibitors or inducers of CYP2B6 (see Section  23, 
Appendix IV). 
Protocol SEP360-311, Version 3.[ADDRESS_29191] is currently undergoing ongoing or newly initiated Cognitive Behavioral Therapy (CBT) 
for the treatment of ADHD; behavioral therapi[INVESTIGATOR_014], including school based interventions that were 
initiated less than one month prior to screening; or, behavioral therapy that in the opi[INVESTIGATOR_29900]‚Äôs ability to participate for the duration of the study.  
School based interventions that have been in place for more than one month prior to screening 
will be allowed.  
Note: Unavoidable changes in school-based interventions that occur during study participation 
will not be exclusionary, but should be documented by [CONTACT_093], to the extent possible. 
Subjects should not be enrolled who, in the judgment of the investigator, are expected to start 
substantially different or more intensive course of behavioral therapy over the duration of their participation in the study.  
10.5. Contraception Requirements  
Female Subjects  
A female subject is eligible to enter and participate in the study if she is of:  
a. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, 
including any female who is premenarchal, surgically sterile, etc.).  
b. Child -bearing potential (all females ‚â• 8 years of age), has a negative pregnancy test at 
screening and agrees to satisfy one of the following requirements:  
‚àí Practice true abstinence (consistent with lifestyle) from signing informed 
consent/assent to at leas t [ADDRESS_29192] dose of study drug; or,  
‚àí Use of medically effective method of birth control from signing informed 
consent/assent to at least [ADDRESS_29193] dose of study drug, which 
include: prescription hormonal contraceptives (oral, patch, vaginal ring, implant, or injection), diaphragm with spermicide, intrauterine device 
(IUD), condom with spermicide, surgical sterilization.  
Male Subjects  
Male subject must be willing to remain sexually abstinent (consistent with lifestyle) or with femal e partner(s) of childbearing potential must ensure that their partner(s) uses the methods of 
birth control as outlined for female subjects above. 
10.6. Guidance for Overdose  
There is no overdose experience with dasotraline in humans. Signs and symptoms of overdose in nonclinical studies were consistent with exaggerated pharmacology and included hyperactivity, stereotypy, aggressiveness, and reduced food intake and body weight loss. 
Activated charcoal may be of value if administered very soon after a dasotraline o verdose (i .e., 
during the absorption process). 
Protocol SEP360-311, Version 3.[ADDRESS_29194] for food. 
During the practice laboratory classroom session and the laboratory classroom days, meals and snacks will be provided as described in the Laboratory Classroom Manual. 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  47 19 November 2017 11. STUDY ASSESSMENTS  
A study schematic is presented in Figure  1. A summary of assessments to be conducted at each 
visit is  presented in  Table 2, Schedule of Assessments.  
Training, as appropriate, will be provided for study site staff administe ring each of the 
effectiveness and safety assessments.  
11.1. Demographics and Baseline Characteristics  
Demographic and baseline characteristics include date of birth, sex, ethnicity, race, and medical 
history. For medical, psychiatric , and family psychiatric his tories, only relevant/significant 
history and recurrence of any condition will be collected.  All medications taken during the 
30 day s before signed consent/assent will be recorded; data collected will be the same as for 
concomitant medications (see Section  10.3). Weight, height, and BMI collection are described in 
Section  11.4.5. Physical and neurological examinations are described in Section  11.4.4. 
11.2. Eligibility Assessments  
Schedule for Affective Disorders and Schizophrenia for School -Age Children Present and 
Lifetime version  (K-SADS -PL) 
The K-SADS -PL will be used at screening to confirm the diagnosis of ADHD.  
The K -SADS -PL is a semi -structured diagnostic interview designed to assess current and past 
epi[INVESTIGATOR_29914]; Text Revision ( DSM -IV-TR) criteria. The 
K-SADS -PL covers a broad spectrum of most child psychiatric diagnoses, with the exception of 
pervasive development disorders and personality disorders. The K- SADS -PL includes questions 
about school performance and other issues relevant to children and adole scents. There is a base 
instrument (82 items) and 5  required diagnostic supplements which are completed depending on 
the results of the base screening: (1)  Affective Disorders; (2) Psychotic Disorders; (3) Anxiety 
Disorders; (4) Behavioral Disorders; (5) Substance Abuse and Other Disorders. 
The K -SADS -PL takes about 45-90 minutes to administer.  
ADHD Rating Scale Version IV - Home Version (modified for investigator administration) 
(ADHD- RS-IV HV)  
The ADHD -RS-IV HV will be used to assess the presence of clinical ly significant ADHD 
symptoms  on Day  -1. 
The ADHD -RS-IV HV was developed to measure the behaviors of children with ADHD. The 
ADHD- RS-IV HV is a validated scale that consists of [ADDRESS_29195] ic and Statistical Manual for Mental Disorders  
Fourth Edition; Text Revision  (DSM -IV-TR) criteria and is also consistent with DSM -5 criteria. 
Each item is scored from a range of zero (reflecting no symptoms) to 3  (reflecting severe 
symptoms) with total sco res ranging from zero to  54. The 18 items may be grouped into 
2 subscales: hyperactivity/impulsivity (even number items  2 through 18) and inattentiveness 
(odd number items 1 through 17). The ADHD- RS-IV HV will be administered to the caregiver 
Protocol SEP360-311, Version 3.[ADDRESS_29196] whenever possible.  
11.3. Efficacy Assessments  
Swanson, Kotkin, A gler, M-Flynn, and Pelham (SKAMP) Scale  
The SKAMP is a validated 13 -item rating scale  that assesses manifestations of ADHD in a 
classroom setting through a combined score and 2 subscale scores; deportment items (interacting 
with other children, interacting with adults, remaining quiet, staying seated, complying with the 
teacher‚Äôs direction s, and following the classroom rules) and attention items (getting started, 
sticking with tasks, attending to an activity, making activity transitions, completing assigned 
tasks, performing work accurately, and being neat and careful while writing or drawi ng). 
Permanent Product Measure of Performance ( PERMP ) 
The PERMP is a [ADDRESS_29197] consisting of 80 problems per page (total of 400 problems). 
Both attempted problems and correct problems will be assessed. Subjects are to complete as 
many problems as po ssible in [ADDRESS_29198]. Parents/guardians should be queried in a non-
leading manner, without specific prompting (if the child has complained about changes in health and how the child has been feeling ). Subjects should also be queried in a non-leading manner, 
without specific prompting (e.g., ‚ÄúHow have you been feeling ? Have you felt different ?). See 
Section  12, Safety Reporting 
AEs and SAEs will be monitored throughout the study at all visits starting after the first dose of 
study drug. 
Untoward medical occurrences that occur prior to the first dose of study drug will be collected as 
pre-treatment events.  
11.4.2. Clinical Laboratory Tests 
The clinical laboratory tests required by [CONTACT_29960]  22, Appendix III . 
Blood and urine samples will be collected for clinical laboratory tests. All clinical laboratory tests will be performed centrally . For detailed instructions regarding clinical laboratory 
procedures, sampling, and shippi[INVESTIGATOR_29915] . Samples will be processed at a central laboratory to ensure consistency . All clinical 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  49 19 November 2017 laboratories will be College of American Pathologists (CAP) and Clinical Laboratory 
Improvement Amendments (CLIA) (or equivalent) certified.  
Any POC  (point of care) kits that are performed on site by  [CONTACT_29961] a lab- 
must be CLIA waived and the study center  must possess a CLIA certificate of Waiver.  
11.4.3. Vital Signs  
Respi[INVESTIGATOR_29916] [ADDRESS_29199]‚Äôs size. Blood pressure and pulse rate should first be taken with the subject in the supi[INVESTIGATOR_2135] ‚â• [ADDRESS_29200] has been 
standing for ‚â• [ADDRESS_29201] develops symptoms consistent with orthostatic hypotension (light-headedness, dizziness, or changes in sensorium upon standing) at any point, 
his or her supi[INVESTIGATOR_29917]. Vital signs will be obtained prior to clinical laboratory collection and performance of an ECG. 
11.4.4. Physical and Neurological Examinations 
Clinically significant physical examination findings, as judged by [CONTACT_093], at screening 
will be recorded as medical history and after screening will be recorded as AEs  or pre -treatment 
events  depending on t he timing in relationship to the first dose of study drug. 
Neurological examination parameters will be assessed by [CONTACT_29962]. 
11.4.5. Weight and Body Mass Index 
Body weight while wearing street clothes and without shoes will be recorded in kilograms (kg). Height without shoes will be recorded in centimeters (cm). Body mass index will be calculated 
by [CONTACT_29963] ( EDC ) system  using height measured at screening and weight from 
the appropriate visit. 
11.4.6. ECGs  
Centrally -read ECG : All ECGs will be obtained in the supi[INVESTIGATOR_2547], after the subject has 
been resting supi[INVESTIGATOR_1919] 5 minutes. ECGs will be 12 -lead with a 10 -second rhythm strip. 
ECGs should be obtained prior to drawing blood samples. All attempts should be made to use the 
same ECG recorder for all visits within individual subjects. ECGs will be centrally read at a core 
lab according to established quality assurance procedures for inter/intra reader variability. Refer 
to Section  20, Appendix I  for additional information. 
Standard [ADDRESS_29202] heart rate (HR), PR interval, RR interval, QT interval, QTc 
with Bazett correction  (QTcB ) and QTc with Fridericia correction (QTcF ) intervals, and QRS 
duration. 
11.4.7. Safety Scales 
Columbia Suicide Severity Rating Scale ( C-SSRS) Children‚Äôs Assessment  
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  50 19 November 2017 The C-SSRS ( Posner-2007) is a tool designed to systematically assess and track suicidal AEs 
(suicidal behavior and suicidal ideation) throughout the study. The strength of this suicide 
classification system is in its ability to comprehensively identify suicidal events while limiting 
the over identification of suicidal behavior. The scale takes approximately 5 minutes to administer. The C- SSRS will be administered by a trained rater at the site.  
This study will utilize 2  versions of the C- SSRS. At the screening visit, the lifetime/recent 
version will be completed; for all subsequent visits the ‚ÄúSince Last Visit‚Äù version of the C-SSRS 
will be administered.  
Subjects who have significant findings for suicidal ideation upon completion of the C- SSRS at 
any time during the study must be referred to the investigator for follow-up evaluation. 
11.5. Study Visits and Assessments 
11.5.1. Screening  
Subjects may be rescreened a maximum of 2 times for out of range cl inical laboratory results, 
insufficient medication washout periods, etc. 
[IP_ADDRESS]. Visit  1 (Day -35 to  -8) 
Subjects will be evaluated at this visit to determine their eligibility to enroll in the study. The 
following study- related procedures will be performed:  
‚Ä¢ Obtai n informed consent/assent 
‚Ä¢ Revi ew inclusion/exclusion criteria  
‚Ä¢ Collect me dical , psychiatric , and family psychiatric histories  
‚Ä¢ Record prior and concomitant medications 
‚Ä¢ Perform physica l and neurological examinations 
‚Ä¢ Measur e height and weight, record BMI 
‚Ä¢ Collect vital signs  
‚Ä¢ Perform ECG  
‚Ä¢ Administer  K-SADS -PL, C-SSRS lifetime/recent version , ADHD -RS-IV HV, math 
pretest for placement level  
‚Ä¢ Collect samples for clinical laboratories (hematology, serum chemistry, TSH, 
urinalysis), UDS, serum pregnancy test for females ‚â• 8 years of age  
[IP_ADDRESS]. Visit  2 (Day  -7): Practice Laboratory Classroom Session 
At this visit the following study- related procedures will be performed:  
‚Ä¢ Review inclusion/exclusion criteria  
‚Ä¢ ADHD- RS-IV HV. Note: The ADHD- RS-IV HV  may be completed in person or by 
[CONTACT_29964] -9, -8, or -7. 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  51 19 November 2017 ‚Ä¢ Record prior and concomitant medications 
‚Ä¢ Collect vital signs  
‚Ä¢ Administer C-SSRS since last visit version  
‚Ä¢ Conduct Laboratory Practice Classroom Session. Details are provided in t he 
Laboratory Classroom Manual. 
[IP_ADDRESS]. Visit  3 (Day -1): Telephone Contact  
[CONTACT_29965]/legal guardian of the subject will be contact[CONTACT_29966]‚Äôs 
continued eligibility for the study. The following study- related procedures will be performed:  
‚Ä¢ Review inclusion/exclusion criteria   
‚Ä¢ Record prior and concomitant medications 
‚Ä¢ Administer ADHD- RS-IV HV  
If a subject does  not demonstrate an ADHD- RS-IV HV total score ‚â• 26 then  he or she is not 
eligible to continue in the study.  
11.5.2. Double -blind Period  
[IP_ADDRESS]. Visit  4 (Day 1): First Laboratory Classroom Day  
At this visit the subject should arrive at the clinic by 6:30  AM and the following study- related 
procedures will be performed: 
‚Ä¢ Record prior and concomitant medications 
‚Ä¢ Review inclusion/exclusion criteria  
‚Ä¢ Measure weight, record BMI  
‚Ä¢ Collect vital signs  once.  
‚Ä¢ Administer C-SSRS since last visit version  
‚Ä¢ Collect samples for UDS, urine pregnancy test for females ‚â• 8 years of age  
‚Ä¢ Randomize to treatment  
‚Ä¢ Dispense study drug 
‚Ä¢ Provide dosing diary 
‚Ä¢ Conduct [ADDRESS_29203]‚Äôs parent/legal 
guardian daily with a reminder to administer study drug.  
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  52 19 November 2017 [IP_ADDRESS]. Visit  5 (Day 15): Second Laboratory Classroom Day 
At this visit the subject should arrive at the clinic by 6:30  AM and the following study- related 
procedures will be performed:  
‚Ä¢ Perform study drug accountability  
‚Ä¢ Collect dosing diary 
‚Ä¢ Record prior and concomitant medications 
‚Ä¢ Record AEs  
‚Ä¢ Measure weight,  record BMI 
‚Ä¢ Collect vital signs once. For each subject the time should be the same as  on Day  1. 
‚Ä¢ Administer C-SSRS  since last visit version  
‚Ä¢ Collect samples for UDS, urine pregnancy test for females ‚â• 8 years of age  
‚Ä¢ Conduct 7 classroom sessions according to the Laboratory Classroom Manual. 
11.5.3. Visit  6 (Day 21 ¬± 2) : End of Study  
Final safety assessments will be completed at this visit. The following  study- related procedures 
will be performed: 
‚Ä¢ Record prior and concomitant medications 
‚Ä¢ Perform physical and neurological examinations 
‚Ä¢ Measure weight, record BMI  
‚Ä¢ Collect vital signs  
‚Ä¢ Perform ECG  
‚Ä¢ Record AEs  
‚Ä¢ Administer C-SSRS since last visit version , ADHD- RS-IV HV  
‚Ä¢ Collect samples for clinical laboratories (hematology, serum chemistry, urinalysis), 
UDS, serum pregnancy test for females ‚â• 8 years of age  
All s ubjects including those who discontinue study drug prior to completion will be asked to 
return 7 (¬±  2) day s after the last dose of study drug and complete the E OS visit. 
After the EOS visit, all subjects will be referred for continuation of their care as determined by 
[CONTACT_093]. Additionally, for subjects who complete the study or discontinue for tolerability 
or lack of efficacy reasons, the sponsor will provide support for approved ADHD medication costs for up to [ADDRESS_29204]‚Äôs healthcare provider.  
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  53 19 November 2017 12. SAFETY R EPORTING  
12.1. Definitions 
12.1.1. Adverse Events  
An adverse event (AE) is any untoward medical occurrence associated wit h the use of a drug in 
humans, whether or not considered drug related . 
Untoward medical occurrences that occur between the time of informed consent/assent and first 
study drug administration are pre -treatment events. Those that occur after first administra tion of 
study drug are considered AEs. 
An AE can , therefore, be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease occurring after the administration of a medicinal (investigational) 
product, whether or not considered related to the medicinal (investigational) product. AEs may include the onset of new illness and the exacerbation of pre-existing conditions. A Es will be 
collected from after first administration of study drug to the last study visit. 
Lack of ef ficacy may be an expected potential outcome and should not be reported as an AE 
unless the event is unusual in some way. 
New signs and symptoms of underlying disease, or signs and symptoms of emerging diseas e 
must be recorded as AEs.  
The Investigator should attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. In such cases, the diagnosis should be documented as the AE 
and not the individual signs/symptoms. 
12.1.2. Serious  Adverse Events  
A serious adverse event (SAE) is an AE that meets one or more of the following criteria:  
‚Ä¢ Results in death. 
‚Ä¢ Is life-threatening.  
‚Ä¢ Requires hospi[INVESTIGATOR_1081]. 
‚Ä¢ Results in persistent or significant disability  or incapacity.  
‚Ä¢ Is a congenital anomaly  or birth defect. 
‚Ä¢ Is an important medical event that may jeopardize the subject  or may require a 
medical or surgical intervention to prevent one of the outcomes listed above. 
Examples of such medical events include allergic bronchospasm requiring intens ive 
treatment in an emergency room or at home, blood dyscrasias or convulsions  that do 
not result in inpatient hospi[INVESTIGATOR_059] . 
The term "severe" is often used to describe the severity of a specific event (as in mild, moderate, 
or severe myocardial infarct ion) (s ee Section  12.3); the event itself, however, may be of 
relatively minor medical significance (such as severe headache). This is not the same as 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  54 19 November 2017 "serious," which is based on subject /event outcome or action criteria usually associated with 
events that pose a threat to a subject 's life or functioning as defined by [CONTACT_29967]. 
During the study, if a subject  has a hospi[INVESTIGATOR_29918] (e.g., elective surgery) that was 
scheduled before the s tudy e ntry, i.e., before informed consent for an event/condition that 
occurred before the study, the hospi[INVESTIGATOR_29919] a therapeutic intervention and not the 
result of a SAE. However, if the event/condition worsens during the study, it should be reported 
as an AE (or SAE, if the event/condition results in a serious outcome such as prolongation of hospi[INVESTIGATOR_059]).  
Life-threatening means that the subject was, in the view of the Investigator, at immediate risk of 
death from the event as it occurred. This definition does not include an event that had it occurred in a more severe form might have caused death.  
SAE criteria information will be captured on the CRF. 
12.2. Objective Findings 
Clinically significant abnormal objective findings (e .g., clinical laborator y value, ECG value, and 
physical examination observation) will also be recorded as  AEs. 
When a clear diagnosis is available that explains the objective findings, this diagnosis will be recorded as the AE, and not the abnormal objective finding (e.g., viral hepatitis will be recorded as the AE, not transaminase elevation). If a definite diagnosis is not available, then record the 
sign (e .g., clinically significant elevation of transaminase levels) or symptom (e .g., abdominal 
pain) as the AE.  
Clinical laboratory test results will be reviewed by [CONTACT_737]. The Investigator must 
determine the clinical significance of all out of range values. Clinical laboratory test with 
possibly drug- related or clinically relevant abnormal values of uncertain causality may be 
repeated. Any abnormal values that persist should be followed at the discretion of the 
Investigator. Laboratory reports will be initialed and dated on all pages by [CONTACT_737]. 
Clinical Laboratory Tests Outside the Normal Range: Any value outside the normal range will be 
flagged for the attention of the Investigator or appropriate designee at the study center. The 
Investigator or appropriate designee will indicate whether or not the value is of clinical significance. If the result of any test (or  repeat test, if done) from the samples taken during 
Screening  is indicated as clinically significant and is not covered by [CONTACT_29968]  8, the subject will not be allowed into the study. Additional testing during the 
study may be done if medically indicated. If a clinically significant abnormality is found in the samples taken after dosing, during the study, and/or at the EOS  visit, this should be recorded as 
an AE and the subject will be followed until the test(s) has (ha ve) normalised or stabilised.  
All on -site ECG tracings and ECG over -read reports will be reviewed by [CONTACT_737]. The 
Investigator must determine the clinical significance of all abnormal ECG s. ECG with possibly 
drug- related or clinically relevant abn ormal findings of uncertain causality  may be repeated . Any 
abnormal ECGs that persist should be followed at the discretion of the Investigator. ECG tracings will be initialed and dated on all pages by [CONTACT_737]. 
Protocol SEP360-311, Version 3.[ADDRESS_29205]‚Äôs study records/source 
documents in accordance with the Investigat or‚Äôs normal clinical practice. All pre -treatment 
events and AEs/all AEs must be recorded on the CRF. 
All AEs will be fo llowed until resolution, stabilization of the condition, the event is otherwise 
explained, or the subject is lost to follow-up. 
Each AE is to be evaluated for duration, severity , frequency , seriousness,  action taken with the 
study treatment, outcome, and causal relationship to the s tudy treatment. Definitions for severity , 
frequency , action taken with the study treatment, outcome, and causal relationship to the s tudy 
treatment  are presented below.  
The severity  of AE:  
‚Ä¢ Mild  - Ordinarily transient symptoms tha t do not influence performance of subject‚Äôs 
daily activities. Other t reatment is not ordinarily indicated. 
‚Ä¢ Moderate - Marked symptoms sufficient to make the subject uncomfortable. 
Moderate influence on performance of subject‚Äôs daily activities. Other treatment may 
be necessary.  
‚Ä¢ Severe - Symptoms cause considerable discomfort. Substantial influence on subject‚Äôs daily activities. May be unable to continue the s tudy, and other treatment may be 
necessary.  
The frequency  of AE : 
‚Ä¢ Once ‚Äì an isolated epi[INVESTIGATOR_1865].  
‚Ä¢ Intermi ttent  ‚Äì occurs on two or more separate occasions.  
‚Ä¢ Continuous  ‚Äì does not abate from date of onset to date of resolution. 
The action taken  with the s tudy treatment: 
‚Ä¢ Drug Interrupted  ‚Äì Study drug stopped temporarily. 
‚Ä¢ Drug Withdrawn  ‚Äì Study drug stopped perman ently.  
‚Ä¢ Dose Not Changed  
‚Ä¢ Not Applicable.  
‚Ä¢ Unknown  
The outcome of the AE: 
‚Ä¢ Recovered/Resolved  
‚Ä¢ Recovering/Resolving 
‚Ä¢ Not Recovered/Not Resolved 
‚Ä¢ Recovered/Resolved with Sequelae  
‚Ä¢ Fatal 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  56 19 November 2017 ‚Ä¢ Unknown  
The causal relationship of the AE to the s tudy treatment:  
‚Ä¢ Not related  
o Not related  - Improbable temporal relationship and is plausibly related to 
other drugs or underlying disease.  
o Unlikely - occurred within a reasonable time frame after 
administration/discontinuation of the study drug, but there is a likely 
association of an  intercurrent/underlying medical condition or other drugs.  
‚Ä¢ Related  
o Possible  - occurred in a reasonable time after study drug administration, but 
could be related to concurrent drugs or underlying disease. 
o Probable  - occurred in a reasonable time after study drug administration, is 
unlikely to be attributable to concurrent drugs or underlying disease, and there 
is a plausible mechanism to implicate the study drug. 
o Definite  - occurred in a reasonable time after study drug administration and 
cannot be explained by [CONTACT_29969]. The adverse event should respond to dechallenge/rechallenge, however, this is not 
mandatory before assigning a definite causality.  
The Medical Monitor is the initial contact [CONTACT_29970]. The contact [CONTACT_29971] [ADDRESS_29206] be immediately reported to  the Sponsor: 
‚Ä¢ SAE  
‚Ä¢ Pregnancy  
Emergency contact [CONTACT_29972] 1. 
12.4.1. Serious Adverse Event  
If the Investigator or study center  staff becomes aware of a SAE that occur s in a study subject 
after first administration of study drug through [ADDRESS_29207] participation in the s tudy, the Investigator or an authorized delegate 
should report SAEs ‚Äúspontaneously‚Äù to [COMPANY_003] -PVG if considered at least possibly related to the 
study drug.  
SAEs will be followed until resolution, loss to follow-up, stabilization of condition, or the event 
is otherwise explained.  
Protocol SEP360-311, Version 3.[ADDRESS_29208] be completed and 
signed and sent via fax or email  (see Table 1) to [COMPANY_003] -PVG within [ADDRESS_29209] be signed by 
[CONTACT_29973]. [COMPANY_003] -PVG provides the SAE form used to report SAEs. 
The Sponsor or designee will promptly notify all study centers and Investigators of a SAE that is 
determined to be expedited to the Regulatory Authorities in accordance with  applicable law (s) 
and regulation(s ). These SAEs must be promptly reported to the Institutional Review Board 
(IRB) by [CONTACT_079]  [INVESTIGATOR_29920]. 
12.4.2. Pregnancy  
Pregnancies  that occur from the time of informed consent /assent  through [ADDRESS_29210]  becomes pregnant during the course of the study, she /parent/legal guardian  will be 
instructed to commence discont inuation of the study medication. Further, t he subject / 
parent/legal guardian  (or female partner of male subject) will be instructed to return 
promptly/within [ADDRESS_29211] 
received any additional s tudy medication, will be followed until resolution (ie, termination 
[voluntary or spontaneous] or birth). 
To report a pregnancy, the Pregnancy Event Form must be completed and sent via fax to [COMPANY_003] -
PVG within [ADDRESS_29212] (DSMB) will monitor safety throughout the study. The 
DSMB will be independent of the Sponsor, CRO, and the investigators and will be empowered 
to recommen d stoppi[INVESTIGATOR_29921]. The membership of the DSMB and its 
mandate will be described in a separate DSMB charter.  
Protocol SEP360-311, Version 3.[ADDRESS_29213] FROM 
STUDY/ DISCONTINUATION OF STUDY DRUG  
13.1. Criteria for Subject Termination  
Subject s may terminate th e study participation  at any time for any reason.  
The possible reasons for the termination of study participation  are as follows : 
‚Ä¢ Adverse event.  
‚Ä¢ Lack of efficacy (specify).  
‚Ä¢ Lost to follow- up (specify).  
‚Ä¢ Pregnancy.  
‚Ä¢ Withdrawal by [CONTACT_1130] (specify).  
‚Ä¢ Non-compli ance with study drug (specify) . 
‚Ä¢ Protocol deviation (specify) . 
‚Ä¢ Death . 
‚Ä¢ Other (specify).  
If at any time during the course of the study, in the opi[INVESTIGATOR_689], the subject may 
no longer safely participate due to a change in medical status (e.g., e xperiences an AE, becomes 
pregnant), the subject must be discontinued from the study treatment . 
The reason for discontinuation and information will be recorded on the appropriate CRF. In case 
of death, the date of death should be captured on the CRF. 
Subje cts who prematurely terminate the s tudy participation may  be replaced.  
Subjects who discontinue study drug prior to completion will be asked to return to the clinic  and 
complete the EOS visit 7 (¬±  2) day s later (Section  11.5.3).  
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  59 19 November 2017 14. STUDY TERMINATION  
The Sponsor reserves the right to discontinue the study at this study center or at multiple centers 
for safety or administrative reasons at any time  while safeguarding that early termination does 
not compromise subjects‚Äô safety or well -being . In particular, a study center that does not recruit 
at an acceptable rate may be closed . Should the study be terminated and/or the study center 
closed for whatever reason, all documentation and s tudy medication s pertaining to the stud y 
must be returned to the Sponsor or its representative. 
If, in the opi[INVESTIGATOR_689], clinical observations suggest it may be unsafe to continue, 
the Investigator may terminate part or the entire study after consultation with the Sponsor. 
In the event of s tudy or site termination, subjects will be required to return to the clinic and 
complete the EOS visit 7 (¬±  2) days after their last dose of study drug and provide d with access 
to standard care.  
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  60 19 November 2017 15. STATISTICS  
An analysis of covariance (ANCOVA) will  be applied to evaluate the treatment effect for the 
primary efficacy endpoint between the dasotraline 2 mg/day and placebo groups for the intent- to-
treat (ITT) population. The model will include treatment, mean SKAMP -Combined score at 
baseline, and site as fixed effects. The primary efficacy analysis will be repeated for the per 
protocol (PP) population. To explore the robustness of the primary efficacy analysis of change 
from baseline at Day  15 in ADHD symptoms in mean SKAMP-Combined score, 2 sensitivity 
analyses will be performed, a placebo -based multiple imputation pattern -mixture model (PMM) 
and a tippi[INVESTIGATOR_29901]. 
A similar ANCOVA model, as described above, will be used for the secondary efficacy 
endpoints for the ITT population. 
The Statistical Analysis Plan (SAP) will provide details on the statistical methods planned for 
this study and will be finalized before the study  database lock (DBL).  
15.1. Sample Size  
A post- hoc ANCOVA -LOCF analysis of data from the SEP360-[ADDRESS_29214] of dasotraline 4 mg/day versus placebo in a subset of 
pediatric patients  with ADHD aged [ADDRESS_29215] size in this 
subgroup of 0.95 (LS mean difference at Week [ADDRESS_29216] error of 2.2). Assuming a smaller effect size for dasotraline 2  mg/day vs. placebo than that of dasotraline 4 mg/day vs. 
placebo, an effect size of 0.[ADDRESS_29217] size also  derives from a  data analysi s showing that in a weight -adjusted dose range 
of 0.065 mg/kg to 0.115 mg/kg , the SKAMP effect size was observed to be 0.70. The weight 
adjusted dosing in the proposed study (SEP360-311) will likely range from 0.057 mg/kg to 
0.125 mg/kg  given that s ix yea r old females are expected to be the lightest subjects (CDC 
estimates 16  kg = 3rd percent ile). Thus, the estimated effect size of .[ADDRESS_29218] siz e of 0.7 for dasotraline 2 mg/day compared to placebo on the 
primary efficacy endpoint of mean SKAMP-Combined score obtained from the average of 
7 assessments collected across the 12  hour classroom day, 88 subjects (44 per treatment group) 
will provide 90% power to detect a treatment effect between dasotraline and placebo at the two-sided alpha level of 0.05, based on the two- sample t- test with equal variance procedure.  
The study will target approximately 100  subjects (50 per treatment group) randomized to either 
placebo or dasotraline 2  mg/day in an attempt to have 88 subjects complete the trial (assuming a 
12% overall dropout rate). 
15.2. Analysis Populations  
The analysis populations are defined below. Subjects will be analyzed based on the treatment to 
which they are randomly assigned.  
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  61 19 November 2017 ITT (Intent -to-Treat) population: The ITT population is defined as all subjects who are 
randomized. The ITT population will be used for the efficacy analyses. 
Safety population: The safety population includes all subjects who are randomized and receive at 
least 1 dose of study medication. All safety analyses will be performed using the safety 
population. 
Per Protocol (PP) population: The PP population will consist of all subjects from the ITT 
population without any important protocol deviation (see Section  15.3.3). This supplemental 
efficacy population will be used to assess robustness of the primary analysis results. 
15.3. Data Analysis 
15.3.1. Subject Disposition  
Subject disposition will be summarized  for all randomized subjects. Subjects who complete the 
study and discontinue from the study will be summarized. The reason for discontinuation from the study will also be presented. 
15.3.2. Drug Exposure and Compliance  
A descriptive summary will be performed for exposure to study medication. Treatment 
compliance will be determined and summarized descriptively using the safety population. 
15.3.3. Important Protocol Deviations 
Protocol deviations (PDs) will be collected during monitoring visits. Protocol deviations will be 
placed, but not limited to, into the following categories: concomitant medications, dosing, 
enrollment inclusion/exclusion criteria, laboratory, non-compliance, and other. Each instance of a protocol deviation will be reviewed and determined to be important or minor before the study 
DBL.  
A summary of protocol deviations will be provided as number (%) of subjects with at least 
1 protocol deviation and number (%) of subjects in each category in all randomized subjects. 
The definition of important protocol deviations will be detailed in the study SAP and the subjects 
with important protocol deviations will be pre-identified (prior to unblinding of the study). 
15.3.4. Demographic and Baseline Characteristics  
Demographics (sex, race, ethnicity, age [years], baseline weig ht [kg], height [cm], and BMI 
[kg/m
2]) will be summarized for the safety and ITT populations. Sex, race, age group, and 
ethnicity will be summarized using summary statistics (n and percentage) for categorical 
variables. Age, baseline height, baseline weigh t, and baseline BMI will be summarized using 
summary statistics (n, mean, standard deviation, median, minimum, and maximum) for continuous variables. 
[IP_ADDRESS]. Medical History  
Medical history will be coded using the Medical Dictionary for Regulatory Activities 
(MedD RA). The count and percentage of subjects under each history term, coded by [CONTACT_29974] (SOC) and preferred term (PT) will be summarized using the safety population. 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  62 19 November 2017 [IP_ADDRESS]. Psychiatric History  
Psychiatric history will be summarized by [CONTACT_2681] -5. The count and percentage of subjects under 
each DSM -5 code will be summarized using the safety population. 
[IP_ADDRESS]. Family Psychiatric History  
Family psychiatric history , as reported by [CONTACT_7071]/guardian, will be summarized by [CONTACT_2681] -5. 
The count and percentage of subjects with a ny first degree relative (biological parent or sibling) 
considered to have a DSM -[ADDRESS_29219] appropriate by [CONTACT_29975] , using the safety population. 
15.3.5. Efficacy Analyses 
[IP_ADDRESS]. Primary Efficacy Endpoint Analysis 
The primary endpoint of change from baseline at Day  15 in ADHD symptoms as measured by 
[CONTACT_29947] -Combined score obtained from an average of the 7 assessments collected across 
the 12-hour classroom day (12 to 24 hours postdose) will be evaluated. 
An analysis of covariance ( ANCOVA) model will be applied to evaluate the treatment effect for 
the primary efficacy endpoint between the dasotraline 2 mg/day and placebo groups for the ITT 
population. The model will include treatment, mean SKAMP -Combined score at ba seline , and 
site as fixed effects.  
In addition, the primary efficacy analysis will be repeated for the PP population. 
[IP_ADDRESS]. Secondary Efficacy Endpoint Analysis 
A similar  ANCOVA model , as described above, will be used for the secondary efficacy 
endpoints for the ITT population. 
‚Ä¢ Change from baseline at Day 15 in SKAMP-Combined score at each of the 
assessment times (12 -, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the 
classroom day 
‚Ä¢ Change from baseline at Day 15 in mean SKAMP-Attention subscale score obt ained 
from the 7 assessments collected across the 12  hour classroom day (12 to 24 hour s 
postdose) 
‚Ä¢ Change from baseline at Day 15 in SKAMP- Attention subscale score at each of the 
assessment times (12 -, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the 
classroom day 
‚Ä¢ Change from baseline at Day 15 in mean SKAMP-Deportment subscale score 
obtained from the 7 assessments collected across the 12 hour classroom day (12 to 
24 hours postdose) 
‚Ä¢ Change from baseline at Day 15 in SKAMP- Deportment subscale score at each of the 
assessment times (12 -, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the 
classroom day 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  63 19 November 2017 ‚Ä¢ Change from baseline at Day [ADDRESS_29220] Problems scores 
at each of the assessment times (12 -, 14-, 16-, 18-, 20-, 22-, and 24-hours postdose) 
during the classroom day 
‚Ä¢ Mean SKAMP -Combined score from the 7 assessments collected across the 12  hour 
classroom day (12 to 24 hours postdose) on Day  15 
‚Ä¢ SKAMP -Combined score at each of the assessment times (12 -, 14-, 16-, 18-, 20-, 22-, 
and 24-hours postdose) during the classroom day on Day  15 
‚Ä¢ SKAMP -Attention subscale score at each of the assessment times (12 -, 14-, 16-, 18-, 
20-, 22-, and 24-hours postdose) during the classroom day on Day  15 
‚Ä¢ SKAMP -Deportment subscale score at each of the assessment times (12 -, 14-, 16-, 
18-, 20-, 22-, and 24-hours postdose) during the classroom day on Day  15 
‚Ä¢ PERMP -Attempted and Correct Problems scores at each of the assessment times (12 -, 
14-, 16-, 18-, 20-, 22-, and 24-hours postdose) during the classroom day on Day  15 
‚Ä¢ Change from baseline at Day 15 in mean PERMP -Attempted  score obtained from an 
average of the 7  assessments collected across the 12 -hour classroom day (12 to 
24 hours postdose).  
‚Ä¢ Change from baseline at Day [ADDRESS_29221] score obt ained from an 
average of the 7  assessments collected across the 12 -hour classroom day (12 to 
24 hours postdose). 
‚Ä¢ Secondary weight based efficacy analyses will also be conducted on the SKAMP and 
PERMP.  
[IP_ADDRESS]. Adjustment for Multiplicity  
There will be no adjustment  for multiplicity for the primary efficacy analysis, secondary efficacy 
analyses, or safety analyses.  
[IP_ADDRESS]. Subgroup Analysis  
The following safety analyses will be performed using the ITT population. 
‚Ä¢ Gender  
‚Ä¢ Race  
‚Ä¢ Age group (6 - 9 years and 10 - 12 years).  
15.3.6. Safety Analyses 
All safety analyses will be performed on the safety population. Unless specifically specified, all 
safety summaries will be presented by [CONTACT_9086], such as number of subjects (n) and 
percentage for categorical variables and number of subjects (n), mean, standard deviation, 
median, minimum, and maximum for continuous variables. 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  64 19 November 2017 [IP_ADDRESS]. Adverse Events  
All AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA)  
version 19.[ADDRESS_29222] medical occurrences: 
‚Ä¢ that occurred on or after the first dose of s tudy medication,  
‚Ä¢ with a missing start date and a stop date on or after the first dose of s tudy medication, 
or 
‚Ä¢ with both a missing start and stop date.  
AEs will be summarized by [CONTACT_29976]  (SOC) and Preferred 
Term (PT).  
The following AEs will be summarized and presented by [CONTACT_29977]: 
‚Ä¢ All AEs (including number of events and subject incidence). 
‚Ä¢ Serious AEs. 
‚Ä¢ AEs leading to discontinuation. 
‚Ä¢ AEs by [CONTACT_764] (mild, moderate, severe). 
‚Ä¢ AEs by [CONTACT_29978] (related, or not related).  
‚Ä¢ Serious AEs by [CONTACT_29978].  
‚Ä¢ AEs leading to death.  
The following conventions will be followed in summari zing AEs:  
‚Ä¢ For subject incidence summaries, each subject will be counted only once within each SOC and within each preferred term.  
‚Ä¢ If a subject reports more than one AE within a preferred term and/or a body system, the AE with the highest known severity within each body system and within each 
preferred term will be include d in the summaries by [CONTACT_926].  
‚Ä¢ For summaries by [CONTACT_29979], AEs will be grouped as 
‚Äúrelated‚Äù or ‚Äúnot related.‚Äù AEs assessed as ‚Äúpossible,‚Äù ‚Äúprobable,‚Äù or ‚Äúdefinit e,‚Äù will 
be grouped as ‚Äúrelated.‚Äù If a subject reports more than one AE within the same 
treatment regimen, SOC and PT, and any are related, it will be summarized as related. AEs whose relationship to treatment is assessed as ‚Äúnot related‚Äù or ‚Äúunlikely‚Äù will be 
grouped as ‚Äúnot related.‚Äù  
A listing of AEs, as well as a listing of deaths , SAEs , or AEs leading to discontinuation, will be 
presented.  
A listing of AEs of special concern and AEs leading to discontinuation, stratified by [CONTACT_8497] , will 
be presented.  
 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  65 19 November 2017 [IP_ADDRESS]. Clinical Laboratory Assessments 
Summary statistics for protocol- specified laboratory parameters (hematology, serum chemistry, 
and urinalysis) will be provided. Laboratory data will also be summarized by [CONTACT_29980], by [CONTACT_29981] (means, 
standard deviations, medians, ranges), and by [CONTACT_29982]. 
[IP_ADDRESS]. ECGs  
Electrocardiogram interval data (ventricular heart rate, RR, PR, QRS, QT, QTc, QTcB, and 
QTcF) will  be summarized using descriptive statistics for baseline, each postdose evaluation, and 
change from baseline to each postdose evaluation.  
[IP_ADDRESS]. Vital Signs  
Vital signs (respi[INVESTIGATOR_697], body temperature, supi[INVESTIGATOR_29922], supi[INVESTIGATOR_29923], body weight ) will be summarized 
at each visit for the absolute value and 
change from baseline using descriptive statistics.  
[IP_ADDRESS]. Neurological Examination 
Neurological examination assessments will be summarized using summary statistics for categorical  variables (normal/abnormal) by [CONTACT_765].  A shift table for baseline condition vs the worst 
result during the course of the study period (Abnormal > Normal) will be presented by [CONTACT_3148].  
[IP_ADDRESS]. Concomitant Medications  
All medications will be coded using World Health Organization drug dictionary ( WHO- DD). 
The prior medications will include medications reported by [CONTACT_29983] 
[ADDRESS_29223] dose date of  study drug 
Frequency counts and percentages of previous and concomitant medications will be presented by 
[CONTACT_14300] -DD Anatomic Therapeutic Chemical (ATC) classification and preferred term for each 
subject group. 
[IP_ADDRESS]. Columbia -Suicide Severity Rating Scale (C -SSRS)  
The number of subjects having any suicidal behavior or suicidal ideation from the C- SSRS 
evaluation will be summarized.  
[IP_ADDRESS]. Subgroup Analysis  
No subgroup analysis will be conducted for safety endpoints. 15.3.7. Treatment of Missing Data  
Missing data handling for ef ficacy endpoints will be detailed in the statistical analysis plan 
(SAP). No missing data handling will be applied for safety endpoints. 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  66 19 November 2017 15.3.8. Sensitivity Analyses 
To explore the robustness of the primary efficacy analysis of change from baseline at Day  15 in 
ADHD symptoms in mean SKAMP -Combined score, 2 sensitivity analyses will be performed, a 
placebo -based multiple imputation pattern -mixture model (PMM) and a tippi[INVESTIGATOR_29924]. The detail of the sensitivity analyses will be documented in the final SAP.  
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  67 19 November 2017 16. PROCEDURE FOR CLINICAL STUDY QUALITY CONTROL 
/DATA COLLECTION, MANAGEMENT, AND QUALITY 
ASSURANCE  
16.1. Data Collection/ Electronic Data Capture (EDC)  
The results from Screening and data collected during the study (except clinical laboratory test 
resul ts) will be recorded in the subject‚Äôs  electronic CRF.  K-SADS -PL, C-SSRS , 
ADHD- RS-IV HV, SKAMP, and PERMP will be completed on paper and then entered into the 
electronic data capture (EDC) system. The study centers will use an EDC system that is 
compliant w ith relevant FDA regulatory requirements per [ADDRESS_29224]¬Æ. 
Password protected access to the EDC system will be via a secure website. Data queries and data 
corrections will be handled through the same system. All transactions within the ED C system are 
fully documented within an electronic audit trail. Each set of completed CRFs must be reviewed and electronically signed  and dated by [CONTACT_737]. 
16.2. Computerized Systems Used for Source Data  
A list of the computerized systems that will be u sed to create, modify, maintain, archive, retrieve, 
or transmit source data are presented below, pursuant to the Guidance for Industry Computerized Systems Used in Clinical Investigations, May  2007. 
Table 7: Computerized Systems Used for Source Data  
Protocol Step  Computerized System Type or Description  
Obtain  infor med consent  A 
Obtain informed assent  A 
Inclusion/E xclusion criteria A 
Randomization  A,D 
Disp ense study  drug A,D 
Study drug  accountability  A 
Medical  Histo ry A 
Psychiatric  Histo ry A 
Prior/conco mitant medication review  A 
K-SADS -PL A 
Physical examination  A 
Neurological  examination  A 
Height A 
Weight  (including body mass  index) A 
Vital signs  A 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  68 19 November 2017 Table 7: Computerized Systems Used for Source Data  (Continued)  
Protocol Step  Computerized System Type or Description  
Electrocardiogram  (ECG)  C 
Adverse event  monitoring A 
Colu mbia Suicide Seve rity Rating Scale (C-SSRS ) A 
ADHD -RS-IV HV  A 
Classroom Practice Session  A 
SKAMP  A 
Math  pretest for determination of  math level  A 
PERMP  A 
Dosing diary distribution/review  A 
Hematology/Chemistry B 
TSH  B 
Serum Œ≤-hCG  (in females ‚â•  8 years of age)  B 
Urinal ysis B 
Urine  drug screen  A 
Urine  Œ≤-hCG  (in females ‚â•  8 years of age)  A 
Statistical analysis  SAS¬Æ, version  9 or higher  
 A = EDC ( Medidata Rave¬Æ); B = LIMS; C  = Core Lab Over -read; D = IXRS.  
 Abbreviations: ADHD -RS-IV HV = ADHD Rating Scale Version IV Home Version (modified for investigator 
administration), Œ≤-hCG  = beta-human chorionic gonadotropin, EDC  = electronic data capture;  IXRS = interactive 
recognition system; K-SADS -PL = Schedule for Affective Disorders and Schizophrenia for School -Age 
Children- Present and Lifetime version , LIMS  = laboratory information management system , 
PERMP  = Permanent Product Measure of Performance, SKAMP  = Swanson, Kotkin, A gler, M-Flynn, and Pelham 
Scale, TSH  = thyroid stimulat ing hormone . 
16.3. Study Monitoring  
This study will be monitored from initiation to completion  by [CONTACT_13668]. 
Monitoring will include personal visits and telephone communication to assure that the 
investigation is conducted according to protocol and in order to comply with International 
Conference on Harmonization ( ICH) Good Clinical Practice (GCP ). On-site review of CRFs will 
include a review of  forms for completeness and clarity, and consistency with source documents 
available for each  subject . 
16.4. Audits  
The study may be subject to audit by [CONTACT_1034]/designee. If such an audit occurs, the 
Investigator must agree to allow acces s to required subject records. This is dependent on the 
subject granting consent /assent  by [CONTACT_29984] (ICF)/ informed assent 
form (IAF). By [CONTACT_12570], the Investigator grants permission to personnel from the Sponsor or its representatives for on -site monitoring and auditing of all appropriate s tudy 
Protocol SEP360-311, Version 3.[ADDRESS_29225] of the clinical laboratory tests for this 
study. The central laboratory will provide the Investigator, Sponsor/CRO with laboratory certification (s), a dated copy of normal range values for the central clinical laboratory selected to 
analyze clinical specimens. If an exception is granted to use a local laboratory, the Investigator 
must supply the Sponsor/CRO with laboratory certification, lab direc tor‚Äôs curricula vitae  and a 
current, dated copy of normal range values.  
Protocol SEP360-311, Version 3.[ADDRESS_29226]  
The Investigator agrees that the study will be conducted according to the protocol, ICH Good 
Clinical Practice (GCP) , ICH guidelines  and the ethical principles that have their origin in the 
Declaration of Helsinki. The Investigator will conduct all aspects of the study in accordance with 
applicable local law(s) and regulation(s ). 
The Investigator will assure proper implementation and conduct of the study including those 
study-related duties delegated to other appropriately qualified individuals. The Investigator will 
assure that study staff cooperate with monitoring and audits. 
The Investigator must sign and return to Sponsor/ CRO the ‚ÄúInve stigator  Approval " page . 
The Investigator must provide a copy of current curriculum vitae (including a copy of a current medical license, current Drug Enforcement Agency (DEA) license, where applicable) , and 
financial disclosure information . In countries where medical licensure is not issued, the 
following documentation is acceptable, as applicable: 
‚Ä¢ Registration number/stamp with a registration number stated on curriculum vitae . 
‚Ä¢ Appropriate diploma number stated on curriculum vitae . 
‚Ä¢ Copy of the diploma. 
The Investigator must sign and return a completed Form FDA 1572 "Statement of Investigator" to Sponsor/ CRO.  
17.2. Institutional Review Board  
Documented approval for conducting the study from appropriate Institutional Review Board 
(IRB ) will be obtained for all participating study centers  prior to initiation of the study, according 
to ICH GCP, applicable local law(s) and regulation(s). When necessary, an extension, 
amendment or renewal of the IRB approval must be obtained and also forwarded to the Sponsor. 
The IRB mu st supply the Sponsor a list of the IRB membership, and a statement to confirm that 
the IRB is organized and operates according to ICH GCP, applicable law(s) and regulation(s). 
A copy of written IRB a pproval or favorable opi[INVESTIGATOR_29925], informed consent form and 
subject recruitment material (if applicable) must be provided to Sponsor/CRO prior to start of the 
study.  The approval or favorable opi[INVESTIGATOR_29926], identify the clinical protocol by [CONTACT_29985]/or protocol number, 
and include the date that approval or favorable opi[INVESTIGATOR_11744]. The letter must also contain a statement that the IRB complies with the requirements in 21  CFR Part  56 for a s tudy conducted 
under a U S Investigational New Drug  (IND) or ICH GCP, as applicable.  
The Investigator/CRO is responsible for obtaining from the IRB continued review of the clinical research or submitting periodic progress reports, in accordance with applicable regulations, at 
intervals not to exceed one year and (if applicable) as otherwise additionally specified by [CONTACT_29986]360-311, Version 3.[ADDRESS_29227] promptly inform their IRB of all SA Es reported by [CONTACT_29987]/CRO in accordance with applicable 
law(s) and regulation(s). 
17.3. Informed Consent  
The informed consent form and informed assent form will be approved by [CONTACT_1034]/ CRO 
prior to submission to the IRB. The Sponsor/CRO may provide a template informed consent / 
informed assent form to be qualified by [CONTACT_29988]. 
All informed consent /assent  forms must contain the minimum elements as mandated by [CONTACT_29989], applicable local law(s) and regulations and will be subject to Sponsor /CRO  approval as 
well as IRB approval. The Sponsor /CRO  may submit informed consent forms to a central IRB 
for review and approval or favorable opi[INVESTIGATOR_29927].  
Before recruitment and enrollment, each prospective subject /parent/legal guardian will be given 
a full explanation of the study, allowed to read the approved informed consent form and assent form(s), as appropriate, and be provided ample time and the opportunity to ask any questions that may arise. Once all questions have been answered and the Investigator is assured that the 
prospective subject /parent/legal guardian  understands the implications of participating in the 
study, the prospective subject and at least one parent/legal guardian  will be asked to give consent 
to participate in the study by [CONTACT_29990](s), as appropriate . As 
part of the consent process, each prospective subject  and at least one parent/legal guardian  must 
consent to direct access to the subject‚Äôs  medical records for study-related monitoring, auditing, 
IRB review, and regulatory inspection. It should be clearly explained to each prospective 
subject /parent/legal guardian  that participation in each and every clinical visit and assessment is 
expected.  The subject may be discontinued from study medication, but that does not necessarily 
negate the expectation that the subject /parent/legal guardian will continue to participate in the 
study through the final visit/assessment.  The Investigator will provide a copy of the signed 
informed consent form and assent forms to each subject /parent/legal guardian , and will record 
the date of the informed consent and assent on the CRF . 
If an amendment to the protocol changes the subject participation schedule in scope or activity, 
or if important new information becomes available that may be relevant to the subject‚Äôs 
parent‚Äôs/legal guardian‚Äôs  consent /assent , the informed consent/ assent  form(s) must be revised, 
submitted to the IRB for review and approval or favorable opi[INVESTIGATOR_1649]. The revised informed consent /assent  form(s) must be used to obtain consent /assent  from a subject currently enrolled in 
the study if he or she is affected by [CONTACT_29991]. The revised informed consent /assent  form 
must be used to obtain consent from any new subjects who are enrolled into the s tudy after the 
date of the approval or favorable opi[INVESTIGATOR_29928].  
17.4. Subject Privacy 
The Sponsor (or Sponsor representative)  or any designees affirm uphold the subjects 
confidentiality.  The subject will be identified by [CONTACT_19494]; full names will be masked 
Protocol SEP360-311, Version 3.[ADDRESS_29228]‚Äôs personal data shall be  
protected in accordance with appropriate laws and regulations. 
17.5. Protocol Amendments and Emergency Deviations 
All revisions and/or amendments to this protocol must be approved in writing by [CONTACT_29992]. The Investigator will not make any changes to the conduct of the s tudy 
or the protocol without first obtaining written approval from the Sponsor and the IRB, except 
where necessary to eliminate an apparent immediate hazard to a study subject. 
Emergency deviations or modifications may b e initiated without Sponsor or IRB approval or 
favorable opi[INVESTIGATOR_1649], only in cases where the deviation or modification is necessary to eliminate or avoid an immediate apparent hazard to subjects. Emergency deviations or modifications must be 
reported to the Sponsor/CRO and the IRB immediately/within 5 business days of the occurrence, 
or in accordance with applicable regulatory requirements.  
17.6. Records Retention  
The Investigator /the study center must arrange for retention of s tudy records at the study center  
for at least 15  years from time of participation in the study or longer in accordance with 
applicable regulations and Sponsor SOPs. The Investigator /site should take measures to prevent 
accidental or premature destruction of these documents. Documents cannot be destroyed  without 
written Sponsor authorization. The Sponsor will inform the Investigator/ the study center  when 
the destruction of documents is permitted. 
17.7. Inspection of Records  
In the event of an inspection, the Investigator agrees to allow representatives of the Sponsor and  
its representative and , the regulatory authorities‚Äô access to all study records . The Investigator will 
promptly notify the Sponsor /CRO of all requests to inspect a Sunovion-sponsored study by 
[CONTACT_29993] a copy of all such inspection reports. 
17.8. Financial Disclosure  
By [CONTACT_12570], the Investigator agrees to provide to the Sponsor prior to start of study 
accurate financial information to allow the Sponsor to submit complete and accurate certifica tion 
and disclosure statements as required by [CONTACT_29994] (21 CFR Part  54). The 
Investigator further agrees to provide this information on a Financial Disclosure/Certification Form that is provided by [CONTACT_1034]. The Investigator will update this information if there are 
any relevant changes during the conduct of the study and for one year after completion of the study.  
The Investigator also consents to the transmission of this information to the Sponsor for these purposes. This may involve the transmission of information to countries that do not have laws protecting personal data.  
17.9. Publication Policy  
Any formal presentation or publication of data collected as a direct or indirect result of the study will be considered a joint publication by [CONTACT_29995]360-311, Version 3.[ADDRESS_29229] agree not to present data gathered individually or by a subgroup of centers before 
the full, initial publication, unless this has been agreed to by [CONTACT_29996]. 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  74 19 November 2017 18. REFERENCES  
Amor LB, Grizenko N, Schwartz G, Lageix P, Baron C, et al. Perinatal complications in children 
with attention -deficit hyperactivity disorder and their unaffected siblings. Rev Psychiatr 
Neurosci 2005;30(2):120-6. 
Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevanc e to 
treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem 
Behav 2011;99:211-6. 
Aron AR, Poldrack RA. The cognitive neuroscience of response inhibition: relevance for genetic 
research in attention -deficit/hyperactiv ity disorder. Biol Psychiatry 2005;7:1285-92. 
Boonstra AM, Oosterlaan J, Sergeant JA, Buitelaar JK. Executive functioning in adult ADHD: a meta -analytic review. Psychol MEd 2005;35:1097-1108. 
Botting N, Powls A, Cooke RWI. Attention deficit hyperactivity disorders and other psychiatric 
outcomes in very low birthweight children at 12 years. J Child Psychol Psychiat 
1997;38(8):931-41. 
Childress AC, Brams M, Kollins SH, Northcutt J, Padilla A, Turnbow JM. The efficacy and 
safety of Evekeo, racemic amphetamine sulfate, for treatment of attention -deficit/hyperactivity 
disorder Symptoms: A multicenter, dose-optimized, double-blind, randomized, placebo-controlled crossover laboratory classroom study. Journal of Child and Adolescent Psychopharmacology. 2015;25(5):402-14. 
Ferri FF. Attention deficit hyperactivity disorder. Ferri‚Äôs Clinical Advisor 2015. St. Louis, MO: 
Mosby, an imprint of Elsevier; 2014:160-1. 
Gamo NJ, Arnsten AF. Molecular modulation of prefrontal cortex: rational development of 
treatments for psychi atric disorders. Behav Neurosci 2011;125:282-96. 
Goto Y, Hatakeyama K, Kitama T, Sato Y, Kanemura H, et al. Saccade eye movements as a quantitative measure of frontostriatal network in children with ADHD. Brain Dev 2010;32:347-55. 
Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, et al. 
Clinically relevant doses of methylphenidate significantly occupy norepi[INVESTIGATOR_29929]. Biol Psychiatry 2010;68:854-60. 
Hervey AS, Epstein JN, Curry JF. Neuropsychology of Adults with Attention-
Deficit/Hyperactivity Disorder: A Meta -Analytic Review. Neuropsychology 2004; 18;485-503.  
Koblan KS, Hopkins SC, Sarma K, Gallina N, Jin F, et al . Assessment of human abuse potential 
of dasotraline compared to methylphenidate and placebo in recreational stimulant users. Drug 
and Alcohol Dependence 2016;159:26‚Äì34. 
Luna B, Garver KE, Urban TA, Lazar NA, Sweeney JA. Maturation of cognitive processes from 
late childhood to adulthood. Child Dev 2004;75:1357-72. 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  75 19 November 2017 Passarotti AM, Pavuluri MN. Brain functional domains inform therapeutic interventions in 
attention deficit/hyperactivity disorder and pediatric bipolar disorder. Expert Rev Neurother 
2011;11:897-14. 
Perricone G, Morales MR, Anzalone G. Neurodevelopmental out comes of moderately preterm 
birth: precursors of attention deficit hyperactivity disorder at preschool age. SpringerPlus 
2013;22:221. 
Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of 
Suicide Assessment (C CASA): clas sification of suicidal events in the FDA's pediatric suicidal 
risk analysis of antidepressants. Am J Psychiatry 2007;164(7):1035-43. 
Rader R, McCauley L, Callen EC. Current strategies in the diagnosis and treatment of childhood 
attention -deficit/hyperactiv ity disorder. Am Fam Physician 2009;79(8):657-65. 
Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, et al. Dopamine transporter occupancies in the human brain induced by [CONTACT_29997] m ethylphenidate. Am J Psychiatry 
1998;155:1325-31. 
Wigal S,  Greenhill L, Nordbrock E, Connor D, Kollins SH, Adjei A, Childress A, Stehli A, 
Kupper R. A randomized placebo-controlled double-blind study evaluating the time course of 
response to methylphenidate hydrochloride extended- release capsules in children with  attention -
deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 
2014;24(10):562-9. 
Wigal SB and Wigal TL. The Laboratory School Protocol: Its Origin, Use, and New 
Applications. J Atten Disord 2006;10; 92-111. Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF. Validity of the Executive 
Function Theory of Attention- Deficit/Hyperactivity Disorder: A Meta -Analytic Review. Biol 
Psychiatry  2005:57;1336-46. 
Protocol SEP360-311, Version 3.[ADDRESS_29230] read the protocol, SEP360-311, Version 3.00, ‚ÄúDasotraline (2mg) in Children Aged 6 to 
12 Years with Attention -Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, 
Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting ‚Äù, and agr ee that it contains all necessary details for conducting the study and 
to conduct the s tudy in strict accordance with the specifications outlined herein.  
I agree that no additional procedure(s) will be added during the conduct of the s tudy except 
through protocol amendment by [CONTACT_29998]. and after documentation of IRB 
approval. 
Investigator Signature: ____________________________________________________ 
Print Investigator Name: __________________________________________________ Date: ___________________________________________ 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  77 19 November 2017 20. APPENDIX I. CARDIAC SAFETY M ONITORING  (ECG) 
1. Requirements for Testing  
ECG equipment and supplies will be provided by [CONTACT_29999]-
clinic protocol ECG assessments.  
‚Ä¢ All 12 -lead ECGs will be re corded in the same manner.  
‚Ä¢ The study center  personnel must be adequately trained in performing ECGs on the 
specific ECG equipment used in this protocol that is provide d by [CONTACT_30000]. 
‚Ä¢ To the extent possible, the same ECG machine and personnel should be used to acquire a subject‚Äôs ECGs throughout the period of their participation in the s tudy.  
‚Ä¢ ECGs will be recorded with at least one [ADDRESS_29231] Restrictions and Instructions  
‚Ä¢ Prior to ECG acquisition, the subject will have rested 5 minutes in the supi[INVESTIGATOR_29930]. 
3. Reporting  
‚Ä¢ It is the responsibility of the Investigator to perform a safety review of the ECG data for changes from previous assessments and/or emergent cardiac dysfunction, and to determine subjects‚Äô eligibility or continuance in the study.  
‚Ä¢ ECGs will be reviewed, signed and dated by [CONTACT_30001]  1572 (MD or DO) after each ECG collection. The same Investigator should 
review all ECG reports for a given subject whenever possible. 
‚Ä¢ For all ECGs, a report will be provided by [CONTACT_30002]. 
‚Ä¢ The ECG tracing will be kept with subject‚Äôs source documentation and / or CRF 
unless it is specified otherwise. The original ECG and the cardiologist‚Äô s over -read 
will be retained at the study center . 
4. Data Standardization 
ECG data will be transmitted to a centralized cardiac safety vendor and centrally over -read 
and interpreted using standardized procedures. 
 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  78 19 November 2017 21. APPENDIX I I. BODY MASS INDEX DETE RMINATION 
Body mass index (BMI) will be calculated by [CONTACT_30003]‚Äôs height and weight (both 
determined without subject wearing shoes) and using these measurements (in centimeters and 
kilogra ms) in the following formula.  
Formula:  
BMI = weight (kg)  √∑ [height (m) x height (m)]  
BMI will be automatically calculated at screening by [CONTACT_30004] , and not by [CONTACT_7893]. 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  79 19 November 2017 22. APPENDIX III . CLINICAL  LABORATORY TESTS 
The following clinical laboratory tests are to  be performed.  
 
Clinical Safety Panel  
HEMATOLOGY:  (Differential reported as % and absolute value)  
Hemoglobin, Hematocrit, Platelet Count, RBC Count, WBC - Total Count, WBC Differential, 
(Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils) 
 
BLOOD C HEMISTRIES : Alanine aminotransferase (ALT), Alkaline Phosphatase (ALP), 
Aspartate aminotransferase (AST), Bicarbonate (HCO 3), Bilirubin (Total, Direct, Indirect), 
Blood Urea Nitrogen (BUN), Calcium (Ca), Chloride (Cl), Creatinine, Glucose, Magnesium 
(Mg), Phosphorus (P), Potassium (K), Protein (Total), Sodium (Na), Uric Acid, Albumin 
 
URINALYSIS:  Blood, Glucose, Ketones, Leukocyte esterase, Microscopic examination, 
Nitrites, pH, Protein  
 
THYROID PANEL:  Thyroid stimulating hormone (TSH)  
 
URINE DRUG SCREENING : Amphetamines, Barbiturates, Benzodiazepi[INVESTIGATOR_1651], Cannabinoids, 
Cocaine, Cotinine, Methamphetamines, Methadone, Methylenedioxymethamphetamine (MDMA), Phencyclidine (PCP), Opi[INVESTIGATOR_858], Oxycodone 
 
OTHER TESTS:  Serum Pregnancy ( Œ≤-HcG) (in female subjects only  ‚â• 8 years of age ), Urine 
Pregnancy Test (in female subjects only  ‚â• 8 years of age ) 
Laboratory reports will be initialed and dated on all pages by [CONTACT_30005]  1572 (MD or DO). Laboratory test results will be reviewed by [CONTACT_30006]. The Investigator must determine the clinical significance of all out-of- range 
lab values (except drug screens). Possibly drug- related or clinically relevant abnormal values of 
uncertain causality must be repeated. Any abn ormal values that persist should be followed at the 
discretion of the Investigator. 
 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  80 19 November 2017 23. APPENDIX IV.  CLINICALLY RELEVANT CYP2B6 
SUBSTRATES OR INDUCE RS OR INHIBITORS (GENERIC 
NAMES)  
The following drugs are prohibited during this study. 
Substrate  Inhibitor  Inducer  
artemisinin  clopi[INVESTIGATOR_29931]. Drug Interactions: Cytochrome P450 Drug Interaction Table. India na University 
School of Medicine (2007). http://medicine.iupui.edu/clinpharm/ddis/table.aspx. Accessed 
4 March  2016. 
 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  81 19 November 2017 24. APPENDIX V.  GROWTH CHART (MALE).  
 
Protocol SEP360-311, Version 3.00  Dasotraline  
Confidential and Propr ietary  82 19 November 2017 25. APPENDIX VI.  GROWTH CHART (FEMALE). 
 